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The neuropeptide relaxin-3 (RLN3) is produced in response to stress, and has 
been implicated in a variety of behaviours, including arousal, locomotion, feeding 
and anxiety in mouse and rats. The mature peptide, consisting of A- and B-
chains, is evolutionarily conserved, with high sequence similarity in all 
vertebrates. In the zebrafish, expression patterns of the Rln3/Rxfp3 system 
overlap with rodents. Hence, this thesis uses zebrafish to ask whether any of the 
proposed roles of RLN3 based on mammalian anatomy and behaviour are 
evolutionarily conserved. 
  
CRISPR/Cas9 was used to mutate the zebrafish relaxin-3a gene (rln3a). Genetic 
characterisation of CRISPR-injected fish identified a 7 base pair (bp) deletion 
mutation in the rln3a locus, which caused a reduction in rln3a transcripts. The 
novel tank diving assay, analogous to the large open field test in rodents, uses 
natural behaviours such as initial bottom-dwelling and locomotion to evaluate 
anxiety and stress responses in adult fish. When tested with this paradigm, rln3a 
mutants spent less time at the bottom half of the tank in the first minute than WT 
siblings, reflecting a slightly anxiolytic phenotype. The application of additional 
stress prior to the onset of the assay resulted in reduced locomotion in mutants. 
Another stress-related response is dark-induced hyperactivity in larval zebrafish. 
Two-photon imaging revealed that dark stimuli caused depolarisation in the 
lateral PAG neurons, where rln3a expression has been observed in larval 
zebrafish, implicating the involvement of Rln3 in such behaviours. However, using 
the visual motor response assay, a test in which larvae were exposed to repeated 
cycles of light and dark stimuli, no difference in locomotor activity between 
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ix 
mutants and WT siblings was observed. Moreover, although food intake is related 
to stress and associated with Rln3 signalling, the rln3a disruption did not cause 
long-term changes in body weight of mutants in comparison to their WT siblings. 
Mutants displayed increased expression of the paralogue, rln3b, which could 
partially compensate for the loss of rln3a, resulting in a lack of phenotypic 
difference. 
 
Unexpectedly, a single nucleotide polymorphism (SNP) of C/T in the 
158th position of rln3a coding DNA (c.158C>T) was found in the WT siblings, 
which resulted in a non-synonymous mutation in the C-peptide. To test the effects 
of this polymorphism on behaviour, the visual motor response of WT fish 
possessing the T variant (rln3ac.158T) was tested against siblings possessing the 
C variant (rln3ac.158C). In WT siblings of mutants, rln3ac.158T showed increased 
locomotor activity in the first 10 minutes of the dark periods compared 
to rln3ac.158C. However, in non-sibling WT, no difference in activity was detected 
between SNP variants, indicating that genetic background influences such 
behavioural effects. 
  
In conclusion, these studies suggest that the loss of rln3a in zebrafish only mildly 
affects stress responses, locomotor responses to dark stimuli and feeding 
behaviours. Unexpectedly, the c.158C>T polymorphism in the C-peptide was 
associated with hyperactivity in the visual motor response in fish from a specific 
genetic background, suggesting a possible biological role to this undefined 
peptide. 
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1. INTRODUCTION 
1.1 Neuropeptides and behavioural responses to stress 
In response to a threat, adaptive behavioural responses are produced by 
emotional states such as fear and anxiety to counteract stressors. Fear can lead 
to fight or flight responses when a threat is imminent, whereas anxiety involves 
increased arousal, attention and risk assessment to a potential threat (Gray & 
McNaughton 2003, McNaughton & Corr 2004). Multiple brain circuits are 
implicated in fear and anxiety, such as the amygdala, hypothalamus, 
hippocampus and periaqueductal gray (Steimer 2002, Tovote et al. 2015). These 
brain regions act by controlling signalling molecules such as neuromodulators 
and neuropeptides. 
 
Neuropeptides are defined as relatively small protein molecules which modulate 
brain activity (Burbach 2011). In contrast to small molecule transmitters, which 
are stored in small clear core vesicles, neuropeptides are located in dense core 
vesicles and generally require higher levels of stimulation to be released (Purves 
et al. 2004). Neuropeptides tend to have longer lasting effects as they do not get 
reabsorbed by the presynaptic terminal, and are able to act at a distant target 
(van den Pol 2012). Upon binding to their receptors, which are typically G-protein 
coupled receptors (GPCRs), signalling cascades are triggered, modifying 
intracellular ionic concentrations to affect the excitability of the target neuron, 
influencing synaptic output (Marder 2012, van den Pol 2012).  
 
Such properties of neuropeptides on a cellular level modulate the functional 
connectivity of the brain within the restrictions of a fixed anatomical network 
CHAPTER 1 - INTRODUCTION 
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(Getting 1989, Nadim & Bucher 2014). Neuropeptide signalling is complex, 
whereby single neuropeptides are able to control multiple types of behaviours, 
with simple behaviours often being controlled by numerous neurotransmitters 
(Marder & Bucher 2007). Furthermore, is has been established that co-
transmission of small-molecule transmitters with neuropeptides are common, 
providing additional flexibility to neuronal circuits according to spatial and 
temporal profiles of the neurotransmitters (Nusbaum et al. 2017, Vaaga et al. 
2014).  This enables the control of adaptive behavioural responses such as 
arousal, feeding, and defensive mechanisms to threat (Herbert 1993, Taghert & 
Nitabach 2012). Indeed, multiple neuropeptides have been implicated in stress-
related behaviours, such as neuropeptide Y, corticotrophin-releasing factor 
(CRF), arginine vasopressin and oxytocin (Reichmann & Holzer 2016, Rotzinger 
et al. 2010).  A relatively new neuropeptide that is thought to be involved in stress 
responses is relaxin-3 (RLN3) (Kumar et al. 2016, Smith et al. 2014b), which will 
be investigated in this thesis. 
 
1.2 Relaxin-3 
1.2.1 Background – the relaxin family peptides 
Seven members of the relaxin (RLN) family exist in humans: RLN H1, H2, and 
H3; and insulin-like peptides (INSL) 3, 4, 5, and 6. All members of this family 
possess similar primary and tertiary structural characteristics. RLNs are 
translated as a preprohormone with a signal peptide and three peptide chains (B-
C-A). The signal peptide and C-peptide (connecting peptide) are proteolytically 
cleaved, resulting in the mature form consisting of B- and A- chains held together 
by disulphide bonds. The motif (RXXXRXXI/V) is the defining feature of the RLN 
CHAPTER 1 - INTRODUCTION 
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family, which is important for receptor binding (Bathgate et al. 2006, Gundlach et 
al. 2013, Ma & Gundlach 2007).  The four known RLN family peptide receptors 
(RXFP) were found to be leucine-rich repeat containing GPCR (LGR) 7, LGR8, 
GPCR135 (or previously named somatostatin- and angiotensin-like peptide 
receptor, SALPR) and GPCR142, which are more recently called RXFP1-4 
respectively (Halls et al. 2007, Wilkinson & Bathgate 2007). 
 
The RLN family peptides act mostly as hormones in peripheral systems. The 
main functional, circulatory form of RLN in humans is H2 (denoted as RLN1 in the 
rodent orthologue and collectively known as RLN) and was initially discovered to 
have roles for development of the reproductive tract and mammary apparatus for 
mammalian parturition and lactation in pregnant females. Later, RLN was 
discovered to have diverse effects on non-reproductive tissues, such as 
vasodilatory actions which are cardioprotective, reducing fibrosis and promoting 
wound healing, and neutralising allergies (Sherwood 2004). RLN has also been 
discovered to act centrally by regulating osmolarity, blood pressure and 
neurosecretion during pregnancy (Ma & Gundlach 2007). INSL3 has survival and 
anti-apoptotic functions related to its expression and secretion in the Leydig cells 
of the testis (Minagawa et al. 2012, Sagata et al. 2015), whereas INSL5 is an 
orexigenic hormone in the gastrointestinal tract (Grosse et al. 2014).  The other 
INSLs are less well known, with putative roles in placental growth for INSL4 
(Millar et al. 2005), and Sertoli cells in the testies for INSL6 (Lu et al. 2006). The 
endogenous receptor for RLN and RLN1 is RXFP1, while RXFP2 is the receptor 
for INSL3, and RXFP4 for INSL5, but the other ligand-receptor pairings are 
undetermined (Hsu 2003, Liu et al. 2003a, Sudo et al. 2003, Wilkinson & 
Bathgate 2007). 
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The RLN3 gene in human and mouse was originally identified through genomic 
database searches of related peptides from the RLN/INSL family (Bathgate et al. 
2002). Unlike RLN, RLN3 is not found in the circulation, but is predominantly 
localised in the brain, produced within the secretory pathway in neurons, and 
present in dense core vesicles (Ma et al. 2007, Tanaka et al. 2005), consistent 
with its description as a neuropeptide. The endogenous receptor for RLN3 has 
been identified as RXFP3/GPCR135 (Liu et al. 2003b), as RLN3 is the only 
member of the RLN family peptide that binds to RXFP3, and the receptor mostly 
restricted to the brain.  Cell-based assays indicate that RLN3 activation of RXFP3 
causes a decrease in cyclic adenosine monophosohate (cAMP) levels (Liu et al. 
2003b), and interactions with Gi/o (inhibitory/olfactory) proteins lead to increase of 
ERK1/2 (extracellular signal-regulated kinase 1/2) levels (van der Westhuizen et 
al. 2007), although how this relates to effects in vivo is unclear (Smith et al. 
2011). Although there is some degree of cross-reactivity between RLN3 and 
RXFP1 and RXFP4, with RLN3 able to activate them both in vitro and in vivo 
(Wilkinson & Bathgate 2007), RXFP3 is widely considered to be the cognate 
receptor for RLN3. In rats, Rxfp1 is widely expressed in the brain, in a pattern 
which corresponds to Rln binding sites, but does not correspond to areas with 
Rln3 expression (Ma et al. 2006). Rxfp4 mRNA or binding sites are not 
detectable in mouse brain (Sutton et al. 2005), and RXFP4 is a psuedogene in 
rats (Chen et al. 2005). 
 
1.2.2 Brain expression of RLN3 and RXFP3 
Within the brain, RLN3 is found in a localised region of the brainstem – the 
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ventromedial area of the dorsal tegmental nucleus (vmDTg) in the rat (Burazin et 
al. 2002) and in the mouse (Bathgate et al. 2002, Smith et al. 2010), and this 
locus is more commonly known as the NI. Smaller populations of RLN3 neurons 
present in the medial, ventral and lateral PAG, pontine raphe nucleus and the 
area dorsal to the substantia nigra in rats (Ma et al. 2007, Tanaka et al. 2005) 
and mice (Smith et al. 2010). RLN3 mRNA has been detected in macaque (Ma et 
al. 2009b), while the teleost paralogues rln3a and rln3b have also been found in 
zebrafish NI and PAG (Donizetti et al. 2008). In both species, the NI was 
identified and defined by RLN3 expression. There is also a report of RLN3 
immunoreactivity in the dorsal raphe nucleus, pontine reticular nucleus and the 
dorsal and ventral tegmental areas in human brain tissue (Silvertown et al. 2010), 
although expression of RLN3 mRNA was not reported as an important control in 
this study. 
 
 In contrast to the confined expression of RLN3, RLN3-containing nerve axons 
send projections to widespread areas in the brain, which correspond to RXFP3 
receptor localisation (Figure 1.1).  In summary, in the rodent brain, RLN3 
projections and receptors are found in: areas regulating the stress response, 
such as the periventricular nucleus of the hypothalamus, the bed nucleus of stria 
terminalis, the amygdala, the PAG and the periventricular thalamic area; areas 
involved in arousal, sleep and vision such as the dorsal and median raphe nuclei, 
the lateral preoptic area, the superior and inferior colliculus and the 
intergeniculate leaflet (IGL); regions of the hypothalamus that mediate feeding 
and metabolism, such as the lateral hypothalamus, dorsal medial nucleus of the 
hypothalamus, and the arcuate nucleus; the septohippocampal pathway and 
cortical regions involved in RLN3 and higher cognition (Ma et al. 2016, Smith et 
CHAPTER 1 - INTRODUCTION 
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al. 2014b).  These data on RXFP3 expression patterns were amassed from 
studies detecting RLN3-like immunoreactivity, RXFP3 mRNA, and radioactive 
labelling of binding sites using the RLN3 analogue, R3/I5 (Liu et al. 2005) by Ma 
et al. 2007, Sutton et al. 2004, and Tanaka et al. 2005 (for a comprehensive 
compiled description, see Smith et al. 2011). Similar expression patterns were 
seen in mouse brain (Smith et al. 2010).  
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Figure 1.1 RLN3/RXFP3 system in the rodent brain 
Schematic parasagittal representation of the rodent brain, illustrating the 
ascending relaxin-3 system and the distribution of RXFP3 in regions grouped by 
function. Amyg, amygdala; Arc, arcuate nucleus; BST, bed nucleus of stria 
terminalis; Cb, cerebellum; CgC, cingulate cortex; Cx, cerebral cortex; DBB, 
diagonal band of Broca; DG, dentate gyrus; DMH, dorsomedial nucleus of 
hypothalamus; DR, dorsal raphe nucleus; dSN, region dorsal to the substantia 
nigra; DTg, dorsal tegmental nucleus; Hi, hippocampus; Hypo, hypothalamus; IC, 
inferior colliculus; IGL, intergeniculate leaflet; IPN, interpeduncular nucleus; LH, 
lateral hypothalamus; LPO, lateral preoptic area; MLF, medial longitudinal 
fasciculus; MR, median raphe; NI, nucleus incertus; OB, olfactory bulb; PAG, 
periaqueductal gray; PVN, paraventricular hypothalamic nucleus; RSC, 
retrosplenial cortex; S, septum; SC, super colliculus; SuM, supramammillary 
nucleus; Thal, thalamus.  
 
Figure and legend adapted from Smith et al. (2014b). 
 
Smith et al. Relaxin-3/RXFP3 networks and neuropsychiatric disorders
FIGURE 1 | (A,B) Low and high magnification micrographs of a coronal
section through the mouse NI, displaying neurons positive for relaxin-3-like
fluorescent immunoreactivity. The region displayed in (B) is outlined in
(A). The location of the midline (m/l) is indicated with a dotted line.
Anterior-posterior coordinates from bregma, −5.38 mm. Scale bars A,
100 µm; B, 250 µm. (C) Schematic parasagittal representation of the rodent
brain, illustrating the ascending relaxin-3 system and the distribution of
RXFP3 in regions grouped by function. Amyg, amygdala; Arc, arcuate
nucleus; BST, bed nucleus of stria terminalis; Cb, cerebellum; CgC,
cingulate cortex; Cx, cerebral cortex; DBB, diagonal band of Broca; DG,
dentate gyrus; DMH, dorsomedial nucleus of hypothalamus; DR, dorsal
raphé nucleus; dSN, region dorsal to the substantia nigra; DTg, dorsal
tegmental nucleus; Hi, hippocampus; Hypo, hypothalamus; IC, inferior
colliculus; IGL, intergeniculate leaflet; IPN, interpeduncular nucleus; LH,
lateral hypothalamus; LPO, lateral preoptic area; MLF, medial longitudinal
fasciculus; MR, median raphé; NI, nucleus incertus; OB, olfactory bulb;
PAG, periaqueductal gray; PnR, pontine raphé; PVA, paraventricular thalamic
area; PVN, paraventricular hypothalamic nucleus; RSC, retrosplenial cortex;
S, septum; SC, super colliculus; SuM, supramammillary nucleus; Thal,
thalamus.
et al., 2013b). As monoa ines (Nutt et al., 1999; Berridge et al.,
2012) and peptides (Nemeroff, 1992; Brundin et al., 2007; McGo-
nigle, 2011) are established or putative targets for the development
of antidepressant drugs (Willner et al., 2013), the status of relaxin-
3/RXFP3 as a similar and likely interconnected arousal system
suggests a similar therapeutic potential.
Abnormal sleep and the disruption of circadian rhythm are
common symptoms of the major neurodegenerative diseases
(Hastings and Goedert, 2013) and neurological disorders such as
depression (Berger et al., 2003), schizophrenia (Van Cauter et al.,
1991), and anxiety (Monti and Monti, 2000), and the success
of current pharmacological treatments for these diseases appears
Frontiers in Pharmacology | Neuropharmacology March 2014 | Volume 5 | Article 46 | 4
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As the largest population of RLN3 neurons is found in the NI, most RLN3/RXFP3 
networks are described as connections from this primary source. There are 
extensive descriptions of efferent and afferent connections of the rat NI (Goto et 
al. 2001, Olucha-Bordonau et al. 2003), which highly correlate with RLN3/RXFP3 
expression (refer to Ryan et al. 2011 for a detailed comparison of NI projections 
and RLN3/RXFP3 expression). Particularly, neuronal tract tracing studies in 
conjunction with RLN3 immunoreactivity have characterised RLN3-specific 
projections from the NI to the septal area (Olucha-Bordonau et al. 2012), and 
amygdala (Santos et al. 2016) in rats.  
 
Additionally, one RLN3 and RXFP3-rich region in the thalamus, the IGL, was 
demonstrated not to arise from the NI (Tanaka et al. 2005). Neuronal tract tracing 
determined that this region was mostly innervated by the PAG population of 
RLN3-containing cells, but scarcely by NI neurons (Blasiak et al. 2013). In this 
study, IGL cells were also shown to be responsive to RLN3, as the application of 
RLN3 analogue R3/I5 hyperpolarised 67% and depolarised 33% of the recorded 
IGL neurons. 
 
1.2.3 Neurochemistry of RLN3 neurons 
The identification of neurochemical features of RLN3 neurons have been 
important in determining how these cells interact with associated brain networks. 
The NI is predominantly comprised of gamma-aminobutyric acid (GABA), and it is 
likely that all RLN3 neurons from the NI are GABAergic neurons based on 
glutamic acid decarboxylase-65 immunoreactivity, although not all GABAergic 
neurons in the NI express RLN3 (Ma et al. 2007). However, at present it is 
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unclear whether other populations of RLN3 neurons are GABAergic.  
 
One main feature of RLN3 neurons is that most, if not all, RLN3 neurons express 
the CRF type 1 receptor (Tanaka et al. 2005).  In this study, RLN3 neurons had 
increased c-fos mRNA levels in response to both intracerebroventricular (i.c.v.) 
administration of CRF and water immersion-restraint stress, and RLN3 mRNA 
was also increased in the latter case (Tanaka et al. 2005). Furthermore, a repeat 
forced-swim test also produced increased RLN3 levels, an effect that was 
blocked by the CRF1 antagonist, antalarmin (Banerjee et al. 2010). Also, i.c.v. 
administration of CRF caused excitation of a majority of the RLN3 neurons 
recorded in the NI, an effect that was also  observed in brain slices. Conversely, 
NI neurons that were RLN3-negative displayed inhibition by CRF (Ma et al. 
2013).  
 
RLN3-positive neurons in the rat NI co-express the 5-hydroxytryptamine (5HT, 
serotonin) -1A receptor, and 5HT depletion by p-chlorophenylalanine lead to an 
increase in RLN3 expression, implying a regulatory role of 5HT on RLN3 
expression (Miyamoto et al. 2008). Furthermore, administration of the anxiogenic 
drug, FG-7142, in rats before exposure to the elevated plus maze increased c-
Fos activation in both the RLN3 populations in the NI and 5HT-ergic cells in the 
dorsal raphe, suggesting an interaction between the two populations in anxiety-
related behaviours (Lawther et al. 2015). 
 
Dopamine type 2 (D2) receptors were recently identified in the rat NI by 
immunostaining, as well as reverse-transcriptase polymerase chain reaction (RT-
PCR) and western blotting from RNA/proteins extracted from NI tissue (Kumar et 
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al. 2015). Infusion of the dopamine agonist quinpirole into the NI resulted in 
reduced locomotion, as well as during novel-environment induced suppression of 
feeding, suggesting that dopamine is involved in NI-related locomotor behaviours. 
 
1.2.4 Behaviours associated with RLN3 
The behavioural role of RLN3/RXFP3 signalling has been investigated based on 
the known functions of the brain regions containing RXFP3 and target regions of 
the NI, which will be reviewed in this section. A summary of the behavioural 
effects seen in null mutation mouse models (Table 1.1) or effects after 
administration of RXFP3-activating ligands on stress and anxiety behaviours 
(Table 1.2), arousal and cognition (Table 1.3), and feeding and motivation/reward 
(Table 1.4) are also provided.  
 
1.2.4.1 Stress and anxiety 
One of the main characteristics of RLN3 is that it is expressed in response to 
stress-mediated activation of CRF1 receptors. Also, electrical stimulation of RLN3 
neurons leads to the activation of the hypothalamic-pituitary-gonadal axis 
(McGowan et al. 2014). Hence, it is expected that RLN3 would be involved in 
stress and anxiety responses. However, only slight alterations were detected in 
behavioural tests for anxiety such as the large open field or elevated plus maze 
tests, and there are contradictory reports between different groups conducting the 
studies. In mixed background (129S5:B6) Rln3 null mutant mice, strong anxiety 
phenotypes were not found, but after eight weeks of chronic stress, male Rln3 
null mutant mice were more sensitive to the stress, displaying a reduction in body 
weight and increased depressive-like behaviour in the forced swim test (Smith et 
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al. 2009). However, backcrossed Rln3 null mutant mice did not show differences 
in anxiety and stress behaviours compared to WT littermates (Smith et al. 2012). 
Using Rxfp3 null mutant mice, one group reported only slightly decreased anxiety 
phenotypes in the elevated plus maze and light/dark paradigms (Hosken et al. 
2015). Conversely another group reported decreased anxiety reflected by 
increased entry into the open arms of the elevated plus maze, although similar 
effects were not observed in other tests (Watanabe et al. 2011b).  
 
Anxiolytic effects were seen after i.c.v. administration of H3 in rats in both the 
elevated plus maze and shock probe-burying test, and spontaneous locomotion 
was decreased when placed in a novel environment compared to a habituated 
environment, indicating decreased stress levels (Nakazawa et al. 2013). Using a 
specific RXFP3 agonist, RXFP3-A2 (Shabanpoor et al. 2012), a decrease in 
anxiety was only seen in the light/dark box and elevated plus maze test, but not 
the open field test (Ryan et al. 2013a). Interestingly, there was no effect of 
RXFP3-A2 in reducing depressive-like effects in rats that had not been previously 
tested in other paradigms, but only in previously tested rats (Ryan et al. 2013a). 
A similar type of study was conducted using the anxiogenic drug benzodiazepine, 
FG-7142, to elevate levels of anxiety before testing (Zhang et al. 2015). Under 
basal conditions, the agonist RXFP3-A2 did not have any effect on anxiety levels, 
but was anxiolytic after FG-7142 administration in the light/dark box and single-
chamber social interaction test in mice. Furthermore, i.c.v. administration of the 
RXFP3 antagonist R3(B1-22)R (Haugaard-Kedstrom et al. 2011), decreased 
anxiety only in the elevated plus maze, but not in large open field, light/dark box 
or social interaction tests (Zhang et al. 2015). This suggests that RLN3/RXFP3 
signalling may preferentially reduce elevated levels of anxiety in rodents. 
CHAPTER 1 - INTRODUCTION 
           12 
12 
1.2.4.2 Arousal and cognition 
The NI is postulated to be part of the ascending arousal network, and projects to 
the medial septum, which is reported as being the ‘pacemaker’ of hippocampal 
theta rhythm (Goto et al. 2001, Olucha-Bordonau et al. 2003). Indeed, evoked 
field potentials and theta hippocampal rhythm were enhanced by the infusion of 
agonist R3/I5, and blocked by pretreatment of the antagonist, R3(B∆23–27)R/I5 
(Haugaard-Kedstrom et al. 2011) in anaesthetised rats, although there was 
greater variability in awake rats (Ma et al. 2009a).  Furthermore, R3(B∆23–
27)R/I5 impaired spatial memory in a hippocampal-theta rhythm dependent 
spontaneous alternation task (SAT) in rats (Ma et al. 2009a). The SAT also 
increased NI c-Fos activation in NI RLN3-containing cells, implying the 
involvement of the RLN3/RXFP3 system in this task. 
 
Rln3 null mutant mice were also shown to have deficiencies in behavioural 
arousal, being hypoactive during the dark (active) phase of the circadian cycle, as 
reflected by reducing voluntary wheel running and distance travelled in a home 
cage, and increasing bouts of immobility (Smith et al. 2012). The decreased 
wheel running activity in the dark phase was also seen in Rxfp3 null mutant mice 
(Hosken et al. 2015). In mixed background (129S5:B6) RLN3 mutant mice, 
hypoactivity was reported in female mice (Smith et al. 2009). However, studies 
monitoring locomotion during feeding in rats reported that i.c.v. administration of 
H3 (Hida et al. 2006) or injection into the periventricular nucleus (McGowan et al., 
2006) had no effects on locomotor activity. Additionally, i.c.v. administration of 
RLN3 agonist R3/I5 administration increased overall locomotor activity in the light 
(inactive) phase, but antagonist R3(B∆23–27)R/I5 did not produce a difference in 
dark (active) phase activity in rats (Sutton et al. 2009). 
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1.2.4.3 Feeding and motivation/reward 
RLN3 neurons project to the hypothalamus, where dense RXFP3 receptors are 
present and exert neuroendocrine actions (Ganella et al. 2013, McGowan et al. 
2009). As such, many studies have been conducted to elucidate the role of the 
RLN3/RXFP3 system in feeding. Administration of RLN3 in rats was 
demonstrated to have an orexigenic effect (Hida et al. 2006; McGowan et al. 
2005, 2006), and increased food intake and related neuropeptide expression 
changes were more prominent in females than males (Calvez et al. 2015).  When 
the agonist, R3/I5, was used, prominent increases in food intake were observed, 
with the antagonist, R3(B∆23–27)R/I5, blocking these effects (Sutton et al. 2009). 
It must be noted that RLN3 has cross-reactivity with RXFP1, which may confound 
results, but further studies conducted with more specific agonist and antagonist 
peptides did demonstrate the same result (Shabanpoor et al. 2012).  
 
In mice, the antagonist R3(B1-22)R blocked intake of regular and palatable food, 
as well as reducing intake during mild food deprivation, and reduced food 
anticipatory behaviour associated with food restriction, but the RXFP3 agonists, 
H3 and RXFP3-A2, did not increase food intake (Smith et al. 2014a). This study 
highlights the involvement of RLN3 signalling in motivated feeding, and also the 
some likely differences in rat and mouse behaviours (Smith et al. 2014a). Rln3 
null mutant mice studies are complex, with Sutton et al. (2009) reporting a 
decrease in body weight in loss-of-function mutant mice, while other studies 
reported no change in body weight in fully backcrossed mutant mice relative to 
littermates (Smith et al. 2009, 2012; Watanabe et al. 2011b).  
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In relation to the control of feeding behaviour, the RLN3/RXFP3 system has also 
been implicated in obesity in rats. Rats with diet-induced obesity (DIO) develop 
obesity after being fed a high-energy diet, in contrast to diet-resistant rats 
(Lenglos et al. 2014a). Rln3 expression was increased in the NI of DIO rats, and 
during re-feeding, RXFP3 was upregulated, compounding orexigenic effects and 
reversing the effects of caloric restriction (Lenglos et al. 2014b). Moreover, in 
binge-eating prone (BEP) rats that increase their sucrose intake in response to 
stress, Rln3 mRNA levels are increased in the NI with a corresponding increase 
in Rxfp3 mRNA in the PVN and the supraoptic nucleus in the hypothalamus 
(Calvez et al. 2016a). The effects of stress on sucrose consumption of BEP rats 
were blocked by i.c.v. administration of the RXFP3 antagonist, R3(B1-22)R 
(Calvez et al. 2016a). 
 
Based on the effects of RLN3 on the motivational aspect of palatable food intake, 
studies were conducted to examine salt appetite and sucrose preference. After 
salt depletion from standard chow, i.c.v. administration of RXFP3 antagonist 
R3(B1-22)R decreased salt consumption in mice (Smith et al. 2014a). To test 
motivation, sucrose was self-administered by WT and Rxfp3 null mutant mice 
under either fixed or progressive ratios (Walker et al. 2015b). Both WT and Rxfp3 
null mutant mice had similar levels of sucrose self-administration under a low 
fixed ratio reinforcement schedules; however, Rxfp3 null mutant mice had 
reduced sucrose self-administration at a higher fixed ratio, and had a lower 
breakpoint for the progressive ratio scheme, indicating a decreased level of 
motivation in Rxfp3 null mutant mice. 
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Alcohol-seeking behaviour is linked to reward system signalling, and RLN3 
signalling appears to be involved. Rln3 levels in the rat NI, detected by 
densitometry of radiolabelled mRNA, were positively correlated with levels of 
alcohol intake (Ryan et al. 2014).  Alcohol preference at baseline levels were 
similar in Rxfp3 null mutants and WT mice in a free choice assay (Walker et al. 
2015a), or operant conditioning assay (Walker et al. 2015b). Another study 
reported increased alcohol consumption in male Rln3 null mutant mice 
(Shirahase et al. 2016). Notably, male WT control mice did not display dose-
dependent increase in alcohol consumption at concentrations used in other 
studies (9–10%). In a model of alcohol relapse, i.c.v. administration of RXFP3 
antagonist reduced both cue- and stress- induced reinstatement of alcohol in 
alcohol-preferring rats using a two-bottle free choice assay (Ryan et al. 2013b). 
When the RXFP antagonist was infused into the bed nucleus of stria terminalis, 
an area postulated to regulate drug and alcohol seeking with dense Rxfp3 and 
Crf1 expression, both self-administration of alcohol and stress-induced alcohol 
reinstatement was reduced. This was corroborated by a study using Rxfp3 null 
mutant mice, where stress-induced reinstatement of alcohol consumption was 
decreased (Walker et al. 2015a).  
 
Orexin inputs into the NI have been demonstrated, at least in part, to regulate 
alcohol consumption, presumably via effects on RLN3/RXFP3 signalling 
(Kastman et al. 2016). Yohimbine-induced reinstatement of alcohol was 
associated with increased c-fos expression in the NI, and this effect was blocked 
by the administration of an orexin-2 receptor antagonist into the NI (Kastman et 
al. 2016). Electrophysiological studies have also shown that orexin-A depolarises 
RLN3-positive NI neurons (Blasiak et al. 2015), specifically via the orexin-2 
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receptors (Kastman et al. 2016), providing a functional link between orexin-A and 
RLN3 signalling in the NI that contributes to alcohol seeking behaviour. 
 








Table 1.1 Behaviours associated with Rln3/Rxfp3 null mouse mutants 
Gene Species Effect Assay Reference 
Rln3  Mouse ↓ locomotion (females) Automated locomotor cell (Smith et al. 2009) 
  ↑ sensitivity to stress (males) Repeated force swim  
Rln3 Mouse ↓ body weight High fat diet (Sutton et al. 2009) 
Rln3 Mouse ↓ anxiety (slight) Elevated plus maze (Watanabe et al. 2011b) 
  ↑ acoustic startle Startle response test  
Rln3 Mouse ↓ locomotion in active phase Voluntary wheel running (Smith et al. 2012) 
Rxfp3 Mouse ↓ locomotion in active phase Voluntary wheel running (Hosken et al. 2015) 
  ↓ anxiety (slight) Elevated plus maze  
  ↓ anxiety (slight) Light/dark box  
Rxfp3 Mouse ↓ stress-induced alcohol reinstatement Two-bottle free choice (Walker et al. 2015a) 
Rxfp3 Mouse ↓ motivational sucrose consumption Operant self-administration (Walker et al. 2015b) 
Rxfp3 Mouse ↑ alcohol consumption (males) Two-bottle free choice (Shirahase et al. 2016) 







Table 1.2 Stress and anxiety behaviours associated with RXFP3 activation 
Compound Species Effect Assay Reference 
H3 Rat ↓ spontaneous locomotion  Spontaneous locomotion (Nakazawa et al. 2013)  
H3 Rat ↓ anxiety Shock-burying test  
H3 Rat ↓ anxiety Elevated plus maze  
RXFP3-A2 Rat ↓ anxiety  Light/dark box (Ryan et al. 2013a) 
RXFP3-A2 Rat ↓ anxiety  Elevated plus maze  
RXFP3-A2 Rat ↓ anxiety (non-naïve mice) Forced swim test  
RXFP3-A2 Rat ↓ elevated anxiety Light/dark box (Zhang et al. 2015) 
RXFP3-A2 Rat ↓ elevated anxiety Social interaction  
R3(B1-22)R* Rat ↓ anxiety (slight) Elevated plus maze  
* antagonist 
















Table 1.3 Arousal and cognition behaviours associated with RXFP3 activation 
Compound Species Effect Assay Reference 
R3/I5 Rat ↑ locomotion in light (inactive) phase Locomotion (Sutton et al. 2009) 
R3(B∆23–27)R/I5* Rat ↓ spatial memory in SAT SAT (Ma et al. 2009a) 
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Table 1.4 Feeding and motivation/reward behaviours associated with RXFP3 activation 
Compound Species Effect Assay Reference 
H3 Rat ↑ food intake Feeding studies (McGowan et al. 2005) 
H3 Rat ↑ food intake Feeding studies (Hida et al. 2006) 
R3/I5 Rat ↑ body weight Feeding studies (Sutton et al. 2009) 
R3(B∆23–27)R/I5* Rat ↓ agonist-induced body weight Feeding studies  
RXFP3-A2 Rat ↑ body weight Feeding studies (Shabanpoor et al. 2012) 
RXFP3-A3* Rat ↓ agonist-induced weight gain Feeding studies  
R3(B1-22)R* Rat ↓ alcohol self administration Two bottle free choice (Ryan et al. 2013b) 
R3(B∆23–27)R/I5* Rat ↓ stress-induced alcohol reinstatement Alcohol reinstatement  
R3(B1-22)R* Mouse ↓ food intake Feeding studies (Smith et al. 2014a) 
H3 Rat ↑ food intake, females > males Feeding studies (Calvez et al. 2015) 
R3(B1-22)R* Mouse ↓ salt intake Sodium depletion/repletion (Smith et al. 2015) 
R3(B1-22)R* Rat ↓ stress-induced food intake (BEP) Stress-induced binge eating (Calvez et al. 2016a) 
* antagonist 
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1.2.5 Role of RLN3/RXFP3 signalling and potential implications in human 
disease 
Based on putative functions of the NI, along with the distribution of RLN3 
projections and RXFP3 receptors, it has been postulated that RLN3/RXFP3 
systems play a part in the ascending arousal network, being activated in 
response to stressors, exerting control over locomotor behaviour and modulating 
theta rhythm via its multiple targets in the hypothalamus. These systems are 
proposed to be involved in neuroendocrine function, signalling energy balance 
and connecting nutritional status to reproductive function (Ganella et al. 2013, 
McGowan et al. 2009). Behavioural studies in rodents have indeed shown that 
RLN3/RXFP3 networks are involved in behavioural arousal, stress responses and 
anxiety, cognition, motivation, and feeding and metabolism. 
 
Therefore, RLN3/RXFP3 systems have been suggested to be a putative target for 
the treatment of neuropsychiatric diseases (Kumar et al. 2016, Smith et al. 
2014b), although there is currently little evidence or direct clinical relevance. 
Polymorphisms in RLN3 genes have been reported to be associated with various 
metabolic disorders, in a population that was treated with anti-psychotics (Munro 
et al. 2012). Also, high serum levels of RLN3, which were detected by enzyme-
linked immunosorbent assay of human H3 relaxin, were linked with patients with 
metabolic syndrome (Ghattas et al. 2013). In Alzheimer’s patients, neocortical 
levels of putative protein RXFP1 and RXFP3 immunoreactivity seemed to 
correlate with levels of depression, but not Alzheimer’s disease symptoms (Lee et 
al. 2016). While the preclinical studies examining effects of the RLN3/RXFP3 
particularly relating to the NI have been suggestive (reviewed in Kumar et al. 
2016), the link to human disease is weak, prompting additional clinical studies. 
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1.2.6 Rln3 system in fish 
Teleosts possess six RLN family genes, due to an additional round of whole 
genome duplication: rln as an orthologue of RLN (or human RLN2); two 
paralogues of RLN3, rln3a and rln3b; an orthologue of INSL3, insl3; and two 
paralogues of INSL5, insl5a and insl5b (Good-Avila et al. 2009). In mammals, 
RLN underwent weak purifying selection, while RLN3 has the lowest rates of 
substitution, reflecting strong purifying selection and being the most conserved of 
the RLN peptides (Wilkinson et al. 2005).  Conversely, evolutionary pressures 
were different in teleost, where rln, rln3a and rln3b all display strong purifying 
selection, suggesting that rln is closer to rln3 than the mammalian orthologue 
RLN (Good-Avila et al. 2009). An amino acid alignment shows that the B-chain of 
zebrafish Rln is indeed 80% similar to Rln3a and Rln3b, 76% similar to human 
RLN3 and only 44% similar to human RLN1 and RLN2 (Fiengo et al. 2012). The 
A-chain is less conserved, with 45% similarity to Rln3a and Rln3b, 41% similarity 
with human RLN3 and RLN2, and 39% similarity with human RLN (Fiengo et al. 
2012).   
 
In zebrafish, rln3a and rln3b mRNA is localised in similar brain regions to 
mammalian RLN3. Slight differences exist between the paralogues, where double 
in situ hybridisation (ISH) revealed that rln3a is expressed in the NI and PAG, 
while rln3b is only expressed in the NI (Donizetti et al. 2009). Notably, the PAG 
population of rln3-expressing neurons in zebrafish is larger than the putative NI 
group, compared to the small mammalian PAG population in mammalian 
counterpart (Donizetti et al. 2008). Also, there is little or no expression of rln3a 
outside the brain, whereas rln3b expression was detected in the testes and 
ovaries. rln3b is expressed diffusely before 48 hours post fertilisation (hpf), after 
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which expression is restricted to the PAG (Donizetti et al. 2009), whereas rln3a 
expression is detected from 72 hpf, restricted in the PAG and NI (Donizetti et al. 
2009). Due to the similarity of the rate of evolution and the slight differences in 
expression between the two paralogues, it is hypothesised that these duplicates 
have gone through sub-functionalisation, each retaining a partial role of the 
ancestral form (Donizetti et al. 2009, Good-Avila et al. 2009). Interestingly, rln 
was found to be expressed in zebrafish brain, and adults expressing rln in the 
telencephalic region around the anterior commissure, the preoptic area, and the 
NI with rln3a (Fiengo et al. 2012). Oustide the brain, rln is expressed in the 
pancreas and thyroid gland. This may indicate a role of rln in zebrafish as a 
neuropeptide with endocrine functions (Fiengo et al. 2012). 
 
On the other hand, there are 10-11 rxfp genes in teleosts, of which three have 
been paired with central functions of the Rln3, whereby Rxfp3.1 is the receptor for 
Rln3b, and the duplicated Rxfp3.2a and Rxfp3.2b are receptors for Rln3a (Good 
et al. 2012). Other Rxfp3 receptors are postulated to have roles in the peripheral 
nervous system or have endocrine functions, such as Rxfp3.3b, Rxfp3.3a1, 
Rxfp3.3a2 for Insl5a, or Rxfp3.4 (Rxfp3.3a3 in zebrafish) for Insl5b (Good et al. 
2012). Zebrafish expression of the rxfp3.2b mRNA can be found throughout 
embryogenesis, while rxfp3.2a mRNA was only found at the larval stage (Fiengo 
et al. 2013). Rxfp3.2b also shared more common brain localisation compared to 
mammalian RXFP3, being expressed in the optic tectum, thalamus, preoptic 
area, habenula, pineal gland and various nerve nuclei (Fiengo et al. 2013). Of the 
other Rxfp3 paralogues in zebrafish, only rxfp3.1 and rxfp3.3b mRNA were 
expressed in embryonic and larval stages (Donizetti et al. 2015). Rxfp3.1 is the 
proposed receptor for Rln3b, and rxfp3.1 mRNA is expressed in the interrenal 
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gland at the early pharyngula stage (24 hpf), switching expression to the 
rhombencephalic region in the larval stage (48 hpf) (Donizetti et al. 2015). The 
rxfp3.3b receptor displays more widespread mRNA expression, such as in the 
PAG, raphe, and caudal region of the hypothalamus in the brain, and the 
pancreas (Donizetti et al. 2015). These regions correspond to RXFP3 expression 
in mammalian brain, and it is hypothesiszed that duplicated Rxfp3 receptors in 
zebrafish underwent sub-functionalisation (Donizetti et al. 2015). Figure 1.2 
depicts a simplified version of the Rln3/Rxfp3 system in larval zebrafish at 5 days 







Figure 1.2 Rln3/Rxfp3 system in the zebrafish brain 
Schematic of the Rln3/Rxfp3 system in larval zebrafish at 5 dpf. Ligand 
localisation is based on rln3a and rln3b mRNA expression as described by 
Donizetti et al. (2008), whereas receptor localisation is based on Rxfp3.2b mRNA 
expression, as described by Fiengo et al. (2013). 
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There are only a few studies regarding Rln3 function in teleosts. Transcriptomic 
analysis of the brains of threespine stickleback identified the activation of the Rln 
pathway in fish that were exposed to olfactory, tactile and visual cues of a 
predator, indicating a similar role in stress responses compared to mammalian 
studies (Sanogo et al. 2011).  Despite its highly conserved brain functions, Rln3 
in teleosts was also shown to have functions outside the brain. rln3 and rxpf3 
mRNA expression was observed in zebrafish ovarian tissues, and 
immunohistochemistry also identified the peptide in killifish (Wilson et al. 2009). 
H3 was also able to enhance production of 17β-estradiol in maturing follicles of 
killifish, implying functions in reproductive tissues (Wilson et al. 2009).  In 
euryhaline threespine sticklebacks, the relaxin peptide family had osmoregulatory 
functions, with rln, rln3a and rln3b transcript levels changing with salinity 
conditions, particularly rln3b (Kusakabe et al. 2014). Transcriptional profiling of 
zebrafish cardiomyocytes also identified Rln3a as an important player in heart 
regeneration, acting downstream of Stat3 after injury (Fang et al. 2013). Rln3 
administration also increased cardiomyocyte proliferation after Stat3 inhibition 
(Fang et al. 2013). 
 
1.3 Hypothesis and aims 
The research described in this thesis is primarily concerned with elucidating the 
role of the neuropeptide Rln3 in zebrafish behaviour, which is currently unknown. 
Previous studies have shown that RLN3 is the most evolutionarily conserved 
peptide of the RLN family (Wilkinson et al. 2005), where teleost Rln3 evolved 
similarly to mammalian RLN3 (Good-Avila et al. 2009).  There is also evidence for 
the existence of zebrafish Rln3 homologues (Donizetti et al. 2009, Good-Avila et 
al. 2009), with similar receptor expression patterns to those in rodent studies 
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(Donizetti et al. 2009, 2015, Fiengo et al. 2012, 2013), which can be compared in 
Figure 1.1 and Figure 1.2. Hence, a logical hypothesis would be that this 
neuropeptide has a conserved function in zebrafish behaviours. Considering that 
species differences exist between RLN3-mediated behaviours in rats and mice 
are apparent, one can expect disparities in zebrafish and rodent behaviour as 
well. However, using a novel model organism can help to identify commonalities 
between species and consolidate general rules for RLN3 function in behaviour. 
 
The aims of this thesis research are as follows:  
1) Establish mutant lines for the Rln3 system in zebrafish using the 
CRISPR/Cas9 system targeted to both ligand and receptor genes. Genetic 
characterisation of these mutants is important, as CRISPRs will create mosaic 
animals with a variety of insertions and deletions (indels). Furthermore, RNA 
analysis will determine if gene expression is disrupted due to the genetic 
manipulations.  
 
2) Test the effect of these mutations in Rln3 mediated behaviours. Rodent 
mutants display phenotypes in feeding, circadian-dependent arousal and anxiety, 
which can be tested in zebrafish. Zebrafish also display characteristic behaviour 
to an increase or decrease in illumination, called the visual motor response. In 
light of the observations that RLN3 is involved in circadian-cycle dependent 
locomotion in rodents, Rln3 signalling may also be involved in zebrafish 
responses to light or dark stimuli on a shorter time scale. 
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Overall, these approaches will provide insight into Rln3 functions in zebrafish. 
Zebrafish models have several advantages over rodent models, such as ease of 
genetic manipulation, possibility for high throughput behavioural assays, relatively 
simple behavioural repertoire and transparent larvae for imaging, and this could 





Figure 1.3 Hypothesis and aims 
To test the hypothesis that Rln3 has conserved roles in zebrafish behaviour 
compared to rodents, two aims have been established. Firstly, mutants for the 
Rln3 system will be created using the CRISPR/Cas9 system, targeting the ligand 
rln3a and the receptors rxfp3.2a and rxfp3.2b. Multiple mutation screening 
methods such as sequencing, high resolution melt analysis (HRMA) and 
restriction enzyme length polymorphism (RFLP) will be employed for mutation 
detection. Secondly, mutants will be tested in behavioural assays for known Rln3-
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2. MUTAGENESIS OF THE RLN3/RXFP3 SYSTEM 
2.1 Introduction 
To investigate the role of RLN3/RXF3 signalling in behaviour using zebrafish, 
both ligand and receptor mutants were created. Genome editing techniques 
recruit engineered DNA-binding nucleases to create double stranded breaks 
(DSBs) in a targeted locus, which are repaired by non-homologous end-joining 
(NHEJ) to create insertions or deletions (indels), producing mutations. 
Techniques such as zinc-finger nucleases (ZFNs) and transcription activator-like 
effector nucleases (TALENs) (Gaj et al. 2013) have been traditionally used in 
zebrafish to provide precise, efficient methods for genome engineering, but make 
use of protein DNA-binding domains for the recognition of target sites, which is 
costly and hinders the ease of design and usage. 
 
Recently, type II clustered regularly interspaced short palindromic repeats 
(CRISPRs) found in prokaryotic adaptive immune systems with Cas9 (CRISPR-
associated protein 9) nuclease has been developed for genome editing purposes 
(Cong et al. 2013, Jinek et al. 2012, Mali et al. 2013), making use of an RNA-
guided nuclease instead. The system requires the target site to contain a 
protospacer adjacent motif (PAM) of ‘NGG’ to be recognised by a CRISPR RNA 
(crRNA), which, together with a trans-activating RNA (tracrRNA) in the presence 
of Cas9, creates DSBs. The two RNAs can be combined into a single guide RNA 
(sgRNA) (Jinek et al. 2012), simplifying the design and implementation of 
mutating target genes compared to earlier methods (Blackburn et al. 2013, 
Sander & Joung 2014).  
 
CHAPTER 2 – MUTAGENESIS OF THE RLN3/RXFP3 SYSTEM  
29 
Since the development of CRIPSRs for genome editing, the CRISPR system has 
been widely validated in zebrafish (Chang et al. 2013, Hwang et al. 2013a, Jao et 
al. 2013). Zebrafish CRISPR mutants have also been used as models for 
behaviour such as epilepsy and sleep (Grone et al. 2016, Yelin-Bekerman et al. 
2015). 
 
 Here, an optimised protocol is described which allows the generation of mutant 
zebrafish within a week of injection of CRISPR/Cas9 mRNA and sgRNA. The 
sgRNA template was produced by using polymerase chain reaction (PCR) 
instead of lengthy cloning methods (Bassett et al. 2013). Additionally, high 
resolution melt analysis (HRMA) was used as a high throughput method of 
detecting mutants at high sensitivity (Bassett et al. 2013, Talbot & Amacher 
2014). Once mutants have been characterised, restriction enzyme length 
polymorphism (RFLP) provided and quick and inexpensive way to genotype fish 
used in experiments. Furthermore, mutants were checked for RNA expression to 
verify if the mutation resulted in a loss in RNA. 
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2.2 Methods 
2.2.1 Generation of mutants  
Zebrafish rln3 family gene sequences were first obtained from the Ensembl 
database (http://www.ensembl.org) (Yates et al. 2016). Ensembl transcript 
identification (ID) are listed in Table 2.1 for the respective genes from the 2014 
version (Flicek et al. 2014). CRISPR targets were selected within these 
sequences using web-based tools such as ZiFit (http://zifit.partners.org/ZiFiT/) 
(Sander et al. 2007) or CHOPCHOP (http://chopchop.cbu.uib.no) (Montague et 
al. 2014) (Table 2.1, PAM sequence in bold). CRISPRs were chosen to target 
exonic regions in the 5’ end to disrupt important downstream functional domains, 




The sgRNAs for these targets were produced using a PCR-based method to 
create a template for transcription (Bassett et al. 2013). PCR was performed with 
the primers in Table 2.2 using Phusion High-Fidelity polymerase 
(ThermoScientific), where the 18-20 bp target sequence (bolded) is incorporated 
into the forward primer. The product produced was approximately 100 bp long. 
Table 2.1 List of CRISPR targets 







rxfp3.2b ENDSDARG00000061846 AGTGGGAGTCTGAAATGGAGAGG 
rxfp3.1 ENDSDARG00000057410 GGAGATAAACCCGACTTCATGGG 
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The PCR reaction was cycled at (98 °C 30 s, 29 cycles of [98 °C 10 s, 60 °C 30 s, 
72 °C 15 s], 72 °C 10 min, 10 °C forever), and the PCR product was purified with 
the QIAquick PCR purification kit (Qiagen). At least 200 ng purified PCR template 
was used for transcription of sgRNA with the T7 MEGAscript transcription kit (Life 
Technologies) for 2–4 h. After 1 h of DNAse treatment, RNA was recovered using 
ammonium acetate precipitation at –20 °C overnight and then eluted in 20 µL 
nuclease free water. Neat sgRNA solution (5 µg–10 µg) was stored in 1 µL 
aliquots at –80 °C for future use. To make the Cas9 mRNA, the expression vector 
pT3Ts-nCas9n (Addgene plasmid #46757) was linearised using XbaI and 
transcribed using the mMessage mMachine transcription kit (Life Technologies). 
Cas9 mRNA was then capped and polyadenylated using the Poly(A) kit (Ambion). 
After being precipitated in lithium chloride at –20 °C overnight, Cas9 mRNA was 
eluted in 30 µL nuclease free water and stored similarly to the sgRNA. 1 µg of 
linearised plasmid template typically yielded about 900 ng–1.3 µg of mRNA. 
Zebrafish embryos were injected with 1 nL of mixture containing 1 µL neat 




Table 2.2 List of primers for sgRNA template 
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2.2.2 Detection of mutants 
2.2.2.1 DNA extraction and sequencing 
To check for mutagenesis, DNA was extracted from either 2–5 dpf embryos or 
adult fins by digesting in 20 µg/mL Proteinase K solution in TE buffer at 55 °C for 
2 h followed by denaturation of Proteinase K at 95 °C for 10 min. Using 
VectorNTI, primers were designed to flank the CRISPR target site (Table 2.3). 
PCR was conducted using Taq polymerase (ThermoFisher Scientific) and cycled 
at 95 °C 2 min, 29 cycles of (95 °C 30 s, TaOpt 30 s, 72 °C 30 s), 72 °C 10 min, 
10 °C forever), where TaOpt represents the optimal annealing temperature as 
determined by VectorNTI. The mutated sequence was determined by sequencing 
the PCR product with BigDye Terminator v3.1 (Life Technologies) and the 
forward primer. Sequences were aligned to the WT sequence using Geneious 
version 7.1.5 (www.geneious.com) (Kearse et al. 2012).  
 
 
Table 2.3 List of primers for genotyping  
Gene Primer (5’ !  3’) Size TaOpt 
rln3a  F TCTCAGACTTTATCTCGCAGGGTTATCA 481 bp 56.7 °C 
 R TCAAGCAACTTATAGAGCTTAGAGCTGAAA  
rln3a F  GCAAAAAGCACAGAACTTCG 214 bp 60.0 °C 
(HRMA) R  ATGACAGCACGGATGAACTC  
rxfp3.2b F GCGTCATGCTCAGCCGAGTATAA 569 bp 57.6 °C 
 R CTGCAGGTCTGTTAGAGCCAAACC  
rxfp3.1 F ATAAAAAACGCAGCGAGCTGTCAG 780 bp 56.8 °C 
 R CGACGTCTCTTACTTTTCAACGCC  
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2.2.2.2 High resolution melt analysis (HRMA)  
High resolution melt analysis (HRMA) is a quantitative reverse transcription PCR 
(qRT-PCR) based technique that can distinguish PCR amplicon sequences at a 
resolution of 1 bp, making it a sensitive, high-throughput method of mutation 
detection. With HRMA, the melt curve of the qRT-PCR reaction is produced using 
a low ramp rate of 1% during amplicon melting such that slight differences in 
melting temperature due to single bp changes can be detected, as well as 
changes in melt curve shape. The HRMA software (Applied Biosystems) would 
then normalise raw melt curve data and allocate the samples as different 
variants. 
 
Primers were designed using Primer3web version 4.0.0 (http://primer3.ut.ee) 
(Untergasser et al., 2012) of about 20 bp in length to a melting temperature of 
60 °C, flanking the CRISPR cut site (Table 2.3). Amplicons were designed to be 
150–250 bp and checked for a single melt peak using the web-based software 
uMELT (https://www.dna.utah.edu/umelt/umelt.html) (Dwight et al. 2011). This 
was found to be a crucial step for HRMA to be accurate as the analysis is based 
on the melt curve.  
 
Extracted DNA samples were diluted to 20 ng/μL in nuclease-free water and 1 μL 
was used for each reaction. Injected fish samples were tested along with three 
WT controls and a no-template control, all in duplicates as technical controls. The 
reaction mixture was made up following the manufacturer’s protocol, using the 
recommended MeltDoctor (Applied Biosystems) saturating DNA dye. The thermal 
cycler protocol was set to cycle at (95 ºC 10 min, 40 cycles of [95 ºC 15 s, 60 ºC 
1 min], 95 ºC 10 s, 60 °C 1 min, 95 °C 15 s, 60 °C 15 s, 10 ºC forever). Variant 
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calls were analysed using the HRM software to determine mutated fish. The 
mutated sequence was determined by using BigDye (Life Technologies) to 
sequence the HRM product with the forward primer. 
 
2.2.2.3 Restriction enzyme length polymorphism (RFLP) 
WT and mutant alleles were also distinguishable by restriction fragment length 
polymorphism. After DNA extraction and amplifying the rln3a gene (primers used 
in Table 2.3), 4 µL of PCR product was used in a 10 µL digest reaction using SfoI 
and CutSmart buffer (NEB) and incubated at 37 °C for 15 min to 1 h. The 
digested and undigested fragments corresponding to mutant or WT allele could 
be easily resolved on a 1.5% agarose gel by electrophoresis.  
 
2.2.3 RNA analysis 
2.2.3.1 ISH 
4 dpf larval zebrafish in a nacre background were treated with 1-phenyl-2-
thiourea (PTU) before fixing in 4% paraformaldehyde at 4°C overnight and stored 
in methanol at –20 °C. A DIG-labelled probe was generated against the entire 
coding region of the rln3a gene using primers adapted from Donizetti et al. (2009) 
(Table 2.4) with a T3 start site at the 5’ end of the reverse primer (in bold). cDNA 
probes were made and hybridisation was carried out on fixed fish using the 
protocol described by Thisse and Thisse (2008). Labelled larvae were cleared 
and mounted in glycerol. They were imaged using differential contrast 
microscopy, with a 20x 0.5 NA air objective on a Zeiss Imager M2 (Oberkochen, 
Germany) using an AxioCam Hrc camera. A z-stack was collected and processed 
using the Extended Focus function to maintain focus throughout the stack. 
 




Adult fish were iced and decapitated and brains were dissected in ice-cold 
Ringer’s solution (116 mM NaCl, 2.9 mM KCl, 1.8 mM CaCl2, 5 mM HEPES       
pH 7.2). RNA was extracted using the PureLink® RNA Mini Kit (ThermoFisher), 
where freshly dissected whole brains were kept in lysis buffer on ice until all 
brains were dissected, and then homogenised before proceeding with the 
manufacturer’s protocol.  This extraction typically yielded about 100 ng/µL RNA 
with A260/280 values between 1.80 and 2.10. 70 ng of RNA was then reverse 
transcribed into cDNA using SuperScript III First Strand Synthesis System for 
RT-PCR (ThermoFisher), which yielded about 1 µg of cDNA. A control containing 
no reverse transcriptase (RT–) was conducted with each reverse transcriptase 
experiment, to check for genomic DNA contamination. PCR using primers to 
detect the full-length rln3a transcript (Table 2.4) was conducted on cDNA 
samples of WT and mutant fish. 
 
2.2.3.3 qRT-PCR 
Primers were designed using the web-based software Primer3web version 4.0.0 
(http://primer3.ut.ee) (Untergasser et al. 2012). The primers used are listed Table 
2.5, for zebrafish β-actin1 (actb1) as an internal control and the gene-specific 
primer for rln3a. Primer pairs were designed to prevent the nonspecific 
Table 2.4 Primers for rln3a ISH probe 
Primer (5’ !  3’) 
F AAAGCACAGGTAGACCATCAGG 
R AATTAACCCTCACTAAAGGGTGCAGCCCCATTTGCAGCAGG 
 Adapted from Donizetti et al. (2009) 
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amplification of genomic DNA where possible. The actb1 primer spans an exon-
exon boundary, while the rln3a primers are exonic but spanned a large intron. 
The primers were first verified by having a single peak on a post-PCR melt curve, 
which produced single bands after electrophoresis on agarose gel, with no bands 
with the RT– controls.  
 
qRT-PCR was performed using GoTaq® qPCR Master Mix (Promega) on 10 µL 
of 100 ng/µL cDNA using the MyiQ™ Real-Time PCR System (Bio-Rad). The 
PCR reaction was cycled at 95 °C 10 min, 40 cycles of (95 °C 15 s, 60 °C 1 min), 
95 °C 10 s, 60 °C 15 s, 10 °C forever. Ten cDNA brain samples per genotype 
(rln3asq4sj-/- mutants and WT sibling) were tested in triplicates, along with both the 
RT– and no template controls.  A standard curve was plotted to indicate that the 
PCR reaction was close to 100% efficiency. This validated the use of the 
comparative Ct (threshold cycle) method (2-∆∆Ct method) (Livak & Schmittgen 




Table 2.5 List of primers for qRT-PCR 
Gene Primer (5’ !  3’) Amplicon size 
actb1 
 
F AGAGCTATGAGCTGCCTGACG 106 bp 
R CCGCAAGATTCCATACCCA  
rln3a F CGTGCTGTCATCTTCACCTG 167 bp 
 R GGGAGATTTGAGTCAGTGGC  
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2.3 Results 
2.3.1 Genetic characterisation of rln3a mutants  
An understanding of the peptide structure is important in ensuring a loss of 
function when creating a mutant of the rln3a gene. A schematic of the 
preprocessing of RLN3 based on porcine RLN structure, adapted from Bathgate 
et al. (2006), is shown in Figure 2.1A. As a member of the RLN family of 
peptides, which has similar structure to insulin, RLN3 is first translated as 
preprorelaxin-3 (with signal peptide upstream of the B-chain, not depicted) before 
proteolytic cleavage into prorelaxin-3 and subsequently RLN3. An alignment 
between mammalian forms of RLN3 (Homo sapiens, Mus musculus, Rattus 
norvegicus) and its homologues Rln3a and -3b in zebrafish (Danio rerio) revealed 
that the B-chain and A-chain were highly conserved, but not the C-chain (Figure 
2.1B). Important residues in the B-chain and A-chain include the receptor binding 
residues (red), receptor activating residues (yellow) and disulphide bond forming 
residues (blue) (Bathgate et al. 2013). These are present in fish, implying 
similarity in structure and hence function between RLN3 and Rln3a/Rln3b. This 
similarity has been detected before, as RLN3 is thought to be the ancestral form 
of RLN family which has been found to exist before teleosts (Wilkinson & 
Bathgate 2007). Additionally, the B-chain homologue was found in the Japanese 
lamprey (Lethenteron japonicum) by utilising the tblastn function of the Basic 
Local Alignment Search Tool (BLAST) (https://blast.ncbi.nlm.nih.gov/Blast.cgi), 
using the zebrafish rln3a sequence against the genome database 
(http://jlampreygenome.imcb.a-star.edu.sg) (Mehta et al. 2013), implying the 
existence of a more ancestral form of the peptide in a jawless vertebrate. 
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Of the zebrafish paralogues rln3a and rln3b, rln3a displays the same expression 
pattern in the brain as the mammalian homologues - being mostly expressed in 
the NI and PAG (Donizetti et al. 2009) -  while rln3b is only expressed in the PAG. 
Hence, sgRNAs were targeted to two sites in the rln3a locus related to the 
binding region for its endogenous receptor (Figure 2.1C). One site was upstream 
of the receptor-binding region, and the other was within the region.  
 
Sequencing analysis of CRISPR-injected embryos and WT sequences revealed 
two mutant alleles that were present. The first mutant allele, denoted as variant 1, 
had a 7 bp deletion, which resulted in a nonsense mutation. This mutant allele 
has been registered under the name rln3asq4sj in ZFIN, the Zebrafish Model 
Organism Database (www.zfin.org), and will be referred to by this name in 
subsequent text. Translating the mutant allele in silico indicated that the highly 
conserved receptor-binding motif was no longer present, and resulted in a 
premature stop codon (Figure 2.1D). The second mutant allele, denoted as 
variant 2, had a 9 bp insertion which added the amino acids VKL into the B-chain, 
but subsequently preserved the reading frame such that there was no disruption 
in the receptor-binding region, and no stop codon was produced (Figure 2.1E). 
Presumably, this mutation might not change in the peptide’s receptor binding 
activity, and hence this mutant was not used for future behaviour experiments. 
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2.3.2 Genetic characterisation of rxfp3 mutants 
RXFP3 is a GPCR containing extracellular domains - the N-terminus and three 
extracellular loops (exoloop 1, 2 and 3) - which are thought to be involved in 
ligand binding (Bathgate et al. 2013). Acidic residues found in exoloop 2 and 3 
were found to contribute to the binding of the arginine residues in the ligand 
(Bathgate et al. 2013). A peptide alignment of the mammalian forms of RXFP3 
(Homo sapiens, Mus musculus, Rattus norvegicus) and the zebrafish 
homologues Rxfp3.2a, Rxfp3.2b and Rxfp3.1 revealed that while the N-terminus 
is not very conserved, the exoloops have a high similarity, with the acidic 
residues ligand binding residues being present in all zebrafish paralogues (Figure 
2.2A).  
 
CRISPR targets were designed near the 5’ region of the rxfp gene to create a 
mutation early in the gene. A CRISPR target for rxfp3.2b was identified at the 
start codon of the gene (Figure 2.2B), while for rxfp3.1 a target was identified the 
N-terminus (Figure 2.2E). Sequencing analyses revealed multiple mutant alleles, 
where two variants in each receptor subtype were characterised. The rxfp3.2b 
variant 1 allele consisted of a single bp deletion, leading to an early stop codon in 
the N-terminus (Figure 2.2C). The second rxfp3.2b mutant allele, variant 2, 
Figure 2.1 Genetic characterisation of rln3a mutants  
(A) Schematic illustrating the preprocessing of prorelaxin-3 to mature RLN3. (B) 
Peptide alignment of the A-, B- and C- chains of RLN3 from human, mouse, rat and 
zebrafish, where A- and B- chains are highly conserved, but not the C-chain. 
Additionally, the Japanese lamprey was found to have a predicted homologous B-chain 
peptide.  (C) Schematic illustrating the genomic arrangement of zebrafish rln3a, with 
CRISPR targets designed upstream or within the receptor-binding region in the first 
exon. (D) Variant 1 (rln3asq4sj allele) which has a 7 bp deletion that leads to a disruption 
of the receptor binding region and eventually a stop codon. (E) Variant 2 allele 
possessing a 9 bp insertion, inserting the amino acids VKL into the B-chain but not 
disrupting the receptor-binding region. No stop codon was produced. 
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consisted of a 10 bp insertion, leading to an immediate stop codon after the first 
four amino acids (Figure 2.2D). On the other hand, the rxfp3.1 variant 1 mutant 
allele consisted of a 3 bp insertion, after which the reading frame continued and 
no stop codon was produced (Figure 2.2F). The rxfp3.1 variant 2 mutant had a 5 
bp deletion in the N-terminus, leading to an early stop codon before the first 
exoloop (Figure 2.2G). 
  
CHAPTER 2 – MUTAGENESIS OF THE RLN3/RXFP3 SYSTEM  
42 
 
Figure 2.2 Genetic characterisation of rxfp3 mutants 
(A) Peptide alignment for RXFP3 from human, mouse, rat and zebrafish, 
illustrating the exoloops 2 and 3 contain acidic ligand binding residues which are 
conserved between all species presented. (B) Schematic of the rfxp3.2b gene, 
where the CRISPR target was designed at the start codon. (C) rxfp3.2b mutant 
allele variant 1, which consists of a single bp deletion, leading to a stop codon in 
the N-terminus. (D) rxfp3.2b mutant allele variant 2, which consists of a 10 bp 
insertion, leading to a stop codon after the first 4 residues. (E) Schematic of the 
rxfp3.1 gene, where a CRISPR target was designed in the N-terminus. (F) rxfp3.1 
mutant allele variant 1, with a 3 bp deletion and resumed the reading frame after 
the addition of a single F amino acid. (G) rxfp3.1 mutant allele variant 2, which 
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2.3.3 Mutation detection  
CRISPR-induced mutations were determined most reliably via Sanger 
sequencing of PCR products containing the CRISPR target site. However, this 
method can be tedious and expensive to use on each CRISPR-mutated fish, and 
hence additional methods of mutation detection were explored. HRMA was used 
as a sensitive, high-throughput method, where variants from the WT controls 
could be determined in the F0, F1 and F2 generations and verified by sequencing 
of representative fish from each group (section 2.3.3.1). Once the mutation type 
had been determined by sequencing, RLFP analysis (section 2.3.3.2) was used 
as a simple and inexpensive method to routinely genotype fish. 
 
2.3.3.1 High resolution melt analysis 
To determine the mutagenesis level of injected fish, DNA from the fins of 20 
injected fish (F0) was subjected to HRMA using primers designed around 
CRISPR target 1 (Table 2.3). Of the fish screened, 14 were recognised as a 
different variant from WT using HRMA, giving a mutation frequency of 70%. 
Sequencing analysis after HRMA revealed that different types of mutations were 
present. Multiple peaks in the chromatogram indicated mosaicism due to CRISPR 
cuts, which occurred around the target sequence (Figure 2.3). 
 
F1 fish were produced by crossing a single F0 fish to the AB WT strain. HRMA 
detected two variants other than the WT variant from 20 F1 adult fish screened. 
This demonstrated that the mutations were heritable in the offspring. Seven fish 
were of one mutant type, denoted as Mutant 1, while 6 fish were of another 
mutant type, denoted as Mutant 2, giving a total mutation frequency of 65%. 
Sequencing analysis revealed that the variants had two peaks of equal height 
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around the CRISPR cut site, representing heterozygosity. The indels produced 
from the CRISPR cut could then be determined by reading the sequence from the 
peak that does not correspond to WT sequence. Mutant 1 was found to possess 
a 7 bp deletion (referred to as variant 1 in Figure 2.4, or rln3asq4sj in section 2.3.1), 
whereas Mutant 2 had a 9 bp insertion (referred to as variant 2 in section 2.3.1) 
(Figure 2.4). 
 
F1 fish of the same heterozygous phenotype (Mutant 1, rln3asq4s+/-j) were 
incrossed to produce F2 fish. Of 8 embryos that were screened, HRMA was able 
to distinguish the homozygous (rln3asq4sj-/-) mutants (3/8, 37.5%) from the WT 
(2/8, 25%) and heterozygous (rln3asq4sj+/-) mutants (3/8, 37.5%). Sequencing 
analysis showed that homozygous mutants had a clean chromatogram peak after 
the CRISPR cut site, with a distinct 7 bp deletion. Heterozygous fish had 
chromatograms resembling parent fish (Figure 2.5). 
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Figure 2.3 HRMA and sequencing of F0 generation 
(A) Aligned melt curves and difference plots of DNA from 20 injected fish and 3 
WT controls. Graphs depict all fish, WT control, or F0 fish only. From the HRMA, 
green traces represented mutant fish (14/20), while blue traces represent WT 
(6/20). (B) Analysis of 3 sequences. Compared to the WT reference sequences 
shown in blue, different types of mutations were present in injected fish. Multiple 
peaks were present around the CRISPR target sequence, indicating mosaicism 
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Figure 2.4 HRMA and sequencing of F1 generation 
(A) Aligned melt curves and difference plots of DNA from 20 heterozygous 
mutant fish (single mutant F0 x WT outcross) and 3 WT control fish. Graphs 
depict all fish, WT fish or F1 fish only. 3 groups were found in F1 fish, where blue 
traces represent WT. (B) Analysis of 4 sequences. Compared to the WT 
reference sequences shown in blue (6/20), the two groups represent Mutant 1 
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Figure 2.5 HRMA and sequencing of F2  generation 
(A) Aligned melt curves and difference plots of DNA from 8 embryos (Mutant 1 
incross) and 3 WT controls. Graphs depict all fish, WT fish or F2 fish only. From 
the HRMA, 3 groups were found in F2 embryos. Blue traces represent WT. (B) 
Analysis of 6 sequences. Compared to the WT reference sequences shown in 
blue (2/8), the other two groups represent heterozygous mutants (purple traces, 
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2.3.3.2 Restriction enzyme length polymorphism 
Once mutant alleles were characterised, restriction enzyme cut sites within the 
mutated region allowed RLFP analysis as a quick and easy way to distinguish 
mutant and WT alleles. An SfoI cut site is present in the middle of the 481 bp 
amplicon of the rln3asq4sj mutant allele, giving rise to a blunt cut with two smaller 
fragments of 247 bp and 227 bp (Figure 2.6A). This cut site is not present in the 
WT allele.  Before SfoI digest, the 7 bp difference between the mutant and WT 
amplicons is not distinguishable by gel electrophoresis (Figure 2.6B). After digest, 
the WT allele remains uncut at 481 bp, while smaller bands are present at 
247/227 bp if the rln3asq4sj allele is present. 
 
Figure 2.6 Detection of rln3asq4sj mutant allele using RFLP 
(A) Schematic diagram depicting the location of the SfoI cut site within the 474 bp 
amplicon of the rln3asq4sj allele. This cut site is not present in the WT allele. (B) 
Gel electrophoresis of PCR amplicons for WT, heterozygous and homozygous 
DNA samples under the uncut and SfoI-digested conditions. 
 
2.3.4 Summary of mutants created 
The development of a quick workflow for creating and detecting CRISPR mutants 
allowed for the generation of multiple mutants for the rln3a, rxfp3.2b and rxfp3.1 
genes, and producing knockouts of both ligand and receptor in zebrafish. Table 
2.6 summarizes the mutants created using this technique, and documents the 
percentage of mutations detected in both F0 and F1 generations, demonstrating 
the mutagenesis frequency for each target after injection, and the germline 
transmission rate for each mutant allele created. 
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Table 2.6 Summary of mutants created 
sgRNA %(#) Mosaic Adults (F0) %(#) Mutant progeny (F1) Mutant (F1) # Mutation %(#) Mutation type (F1) 
rln3a 70% (14/20) 65% (13/20) Variant 1 7bp del 54% (7/13)  
   Variant 2 9bp in 46% (6/13)  
rxfp3.2b 6.25% (1/16) 89% (17/19) Variant 1 1bp del 53% (9/17)  
   Variant 2 10bp del 47% (8/17)  
rxfp3.1 80% (4/5) 100% (8/8) Variant 1 3bp del 37.5% (3/8)  
   Variant 2 5bp del 25% (2/8)  
   Variant 3 N.D. 12.5% (1/8)  
   Variant 4 N.D. 12.5% (1/8)  
   Variant 5 N.D. 12.5% (1/8)  
Abbreviations: del – deletions, in – insertions, N.D. – not determined 
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2.3.5 RNA Analysis 
2.3.5.1 ISH and RT-PCR 
ISH was conducted to determine the localisation of rln3a transcripts within the 
brain of rln3asq4sj-/- mutants and WT siblings (Figure 2.7A, B). Fish were fixed at 4 
dpf, as the PAG and NI are clearly labelled at this age (Donizetti et al. 2008), and 
this was observed in WT sibling fish (Figure 2.7A). The rln3asq4sj-/- mutants, 
however, only displayed faint labelling (Figure 2.7B).  
 
RT-PCR was used to detect full-length rln3a transcripts from cDNA of whole adult 
fish brains. Samples from WT fish presented strong bands, but only faint bands 
were present in samples obtained from rln3asq4sj-/- mutants (Figure 2.7C). Both 
RT-PCR and ISH verify that RNA levels were reduced in the rln3asq4sj-/- mutant, 
probably due to nonsense-mediated RNA decay mechanisms (Chang et al. 
2007). This implies the lack of a functional peptide in the rln3asq4sj-/- mutant, but 
not in WT siblings. 
 
2.3.5.2 Quantitative expression of rln3a 
qRT-PCR was used to quantify rln3a expression from rln3asq4sj-/- mutants and WT 
siblings, using RNA extracted from whole adult fish brains (n=10). Primers 
demonstrated sufficient efficiency at 99.8% and 99.7% for rln3a and actb1 
respectively, validating the use of the 2-∆∆Ct method (Livak & Schmittgen 2001) for 
analysis (Figure 2.7E, G). The melt curve displayed a single peak for both 
amplicons, indicating specificity (Figure 2.7F, H). This was verified when the PCR 
products were visualised on agarose gel (Figure 2.7D), displaying single bands. 
The negative control without reverse transcriptase revealed no bands, indicating 
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no genomic contamination in the amplification.  
 
The expression levels of rln3a were clearly depleted in the rln3asq4sj-/- mutants 
(∆Ct M = -9.31, 95% CI [-9.69, -8.93]) with an approximately 16-fold decrease 
compared to WT siblings (∆Ct M = -5.32, 95% CI [-5.65, -4.99]) (Figure 2.7I), 
quantifying the lack of rln3a due to the mutagenesis.  
  
CHAPTER 2 – MUTAGENESIS OF THE RLN3/RXFP3 SYSTEM  
52 
 
Figure 2.7 RNA analysis of rln3asq4sj-/- mutant 
(A-B) ISH in 4 dpf larvae, where the PAG and NI are clearly stained in WT sibling 
fish but not in the mutant. (C) RT-PCR of full-length rln3a cDNA produces a 
strong band in WT sibling fish, while a faint band is observed from the mutant, 
implying rln3a depletion due to the mutation (4 representative fish). (D) qRT-PCR 
products display a single band on agarose gel, with no amplification in the RT– 
control. (E-H) Optimisation of primers. Standard curves indicate close to 100% 
efficiency in both primers used (E, G). Melt curves display a single peak, 
indicating specificity of primers to the amplification product (F, H). (I) Expression 
levels of rln3a in mutant and WT sibling fish (n = 10 per group), represented by 
normalised difference in threshold cycles (∆Ct = Ctref – Ctgene). Individual fish 
samples are plotted as unfilled circles, crosses represent mean and error bars 
represent 95% confidence interval of the mean. (J) Fold change of expression, 
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2.4 Discussion 
2.4.1 CRISPR-based protocol for zebrafish mutagenesis 
In the studies described in this chapter, rln3a mutants were created in a zebrafish 
line, which are useful in providing an alternative vertebrate non-rodent model to 
study the functions of RLN3. Zebrafish models are advantageous in neuroscience 
(Guo 2004), as they reproduce quickly and prolifically for high throughput screens 
for behavioural analysis, can be genetically manipulated to produce several 
useful transgenic lines for mapping networks, and the transparent larvae can also 
be imaged for brain activity in vivo (Friedrich et al. 2010, Kalueff et al. 2014). The 
advantage of using a CRISPR-based protocol for zebrafish mutagenesis is that it 
is quick and easy to implement, allowing multiple genes to be targeted and tested 
for mutations simultaneously. 
 
Presented here is an optimised protocol for zebrafish mutagenesis using the 
CRISPR/Cas9 system. Initial methods for creating CRISPR mutations included 
lengthy cloning steps for sgRNA production (Chang et al. 2013, Hruscha et al. 
2013, Hwang et al. 2013a), whereas this protocol uses a PCR-based method 
(Bassett et al. 2013) which dramatically reduces the time required from days to 
hours. This was coupled with a high-throughput screening method, HRMA, to 
increase the number of putative mutants that can be detected (Talbot & Amacher 
2014). Mutants can be made in a week, from design of the CRISPR targets to the 
screening of injected embryos for mutations. However, it should be noted that not 
all the gene locations targeted were effectively mutated. For example, despite 
attempting to mutate the paralogue rln3b using 11 different sgRNAs, no mutation 
could be detected. This indicates that some genomic locations are more 
accessible for CRISPR cutting than others. 
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One way in which this protocol could be improved is to increase the mutagenesis 
frequency of the sgRNAs used, to enhance efficiencies in cutting, which range 
from 6.25% to 80% of injected embryos possessing mutations (Table 2.6). This is 
in line with various studies that also indicate target sequence-dependent 
mutagenesis efficiencies (Auer et al. 2014b, Burger et al. 2016, Gagnon et al. 
2014, Hwang et al. 2013b, Jao et al. 2013, Varshney et al. 2015). Recent reports 
report that the efficiency of cutting can be increased by using a ribonucleoprotein 
complex for injection instead of the Cas9 mRNA, to ensure the activity of the 
Cas9-sgRNA complex before microinjection (Burger et al. 2016, Gagnon et al. 
2014), which could be implemented to improve the mutagenesis frequency.  
 
2.4.2 Genetic characterisation of zebrafish mutants 
Although CRISPR mutants could be made and identified quickly, screening for 
mutants that could be used for behavioural analysis was a larger challenge. It is 
evident that the F0 generation of CRISPR injected mutants possessed a high-
level of mosaicism (Table 2.6), which could produce too much variability for 
behavioural experiments.  Mosaicism occurs when CRISPRs cut the genome at 
different stages, and could be prevented by using active ribonucleoprotein 
CRISPR complexes that are saturating, such that cuts occur at the single-cell 
stage before division to produce limited mutant alleles (Burger et al. 2016). 
Furthermore, indels produced in multiples of three are unlikely to confer any 
change to the codon-reading frame, which might not disrupt protein function.  As 
such, only alleles that lead to a production of a stop codon were used to 
propagate future generations, where minimally the F2 generation would result in 
homozygous mutants for behaviour testing. Obtaining clean lines with this criteria 
required stringent screening protocols to ensure that differences in behaviour 
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could be attributed to a specific mutation type. 
 
In this protocol, Sanger sequencing was used as the definitive method to 
determine mutagenesis, as sequences are clearly determined and the quality of 
reads can be defined. However, it is costly to run if many samples require 
processing. Hence, HRMA was employed due to its high sensitivity and high-
throughput application, as well as the availability of a compatible qRT-PCR 
machine. HRMA managed to reliably detect mutations in the F0, F1 and F2 
generations of CRISPR mutants (Figure 2.3, Figure 2.4, and Figure 2.5 
respectively) compared to Sanger sequencing. However, due to its high 
sensitivity, it required a high level of accuracy, especially in starting DNA 
concentration. This made it susceptible to errors due to pipetting inaccuracies or 
poor DNA quality, sometimes necessitating the use of Sanger sequencing to 
validate results. Frequent calibration of the machine was also required to 
maintain the quality of the results. Furthermore, there is limited choice for primer 
design to ensure accurate sequence detection. Some genomic loci may not be 
able to fit the criteria of having a single melt peak, immediately disqualifying the 
use of HRMA. A small amplicon of 150 bp–250 bp may not cover multiple target 
sites, such that only a small mutation region can be analysed at once. As such, it 
was difficult to obtain consistent results with multiple gene sets, and Sanger 
sequencing of PCR results proved to be more reliable. 
 
Once mutation sequences were determined, RFLP proved to be a simple method 
to determine if offspring from a heterozygous incross were homozygous or 
heterozygous for WT or mutant alleles. Indels produced by CRISPR cuts are 
typically small (< 10 bp) and hard to resolve on agarose gel unless amplicons can 
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be differentially cut. Restriction enzyme digest is a technique that does not 
require much precision, and results were less ambiguous compared to HRMA. 
Restriction enzymes can also digest in as little as 15 minutes, which is faster than 
Sanger sequencing. However, this method is only applicable if there is a 
restriction site available to distinguish the WT from mutant allele, and would be 
more difficult when indels are smaller. 
 
The mutation screening methods presented here are unable to detect the full 
amounts of mosaicism present in F0 injected embryos, for which deep 
sequencing is required, but which is costly to run (Burger et al. 2016, Gagnon et 
al. 2014). Cloning PCR products would be a more cost effective strategy, but is 
tedious and might be insufficient to detect low frequency alleles. An alternative 
would be to use fluorescent PCR coupled with capillary electrophoresis for high-
throughput analyses at single bp resolution, which is more informative than 
HRMA, being able to determine allele length of various alleles in mosaics 
(Ramlee et al. 2015, Varshney et al. 2015), if such capabilities are available.  
 
To ensure pure mutant lines for behavioural analyses despite our limited mutation 
detection capabilities, at least two outcrosses were performed to dilute residual 
mosaic or off target effects. Initially, multiple ligand and receptor genes were 
targeted with the intention of testing for effects in the various related genes, or 
produce double knockout mutants. However, the mosaicism produced by 
CRISPR/Cas9 caused difficulties in mutation screening, which made it 
increasingly difficult to maintain multiple mutation lines concurrently. To ensure 
that experiments were done with well-characterised mutants, only the rln3asq4sj-/- 
mutant line was used for further behavioural analyses.  
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Being a relatively new technique, there has been some concern about off-target 
effects in CRISPR mutations, as guide RNAs are short at approximately 20 bp. 
However, detectable off-target effects have been shown to be low (Hruscha et al. 
2013, Varshney et al. 2015) and found to be preventable depending on how 
target RNAs were chosen (Cho et al. 2014). In making the zebrafish mutants for 
the RLN3 system, sgRNA targets were chosen to have no predicted off-target 
effects as analysed by the web-based tools CHOPCHOP and ZiFit, and no 
similar sequences when searched in BLAST. In subsequent years after the 
mutant generation, an off target that contained two mismatches, at the bp 6 and 8 
of the sgRNA, and was located on chromosome 13. This locus was screened and 
no mutation was detected. 
 
With no known off-target effects, and with at least two generations of outcrossing, 
the CRISPR-generated rln3asq4sj-/- mutants were tested for behavioural changes. 
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3. BEHAVIOURAL PHENOTYPING OF RLN3A MUTANTS 
3.1  Introduction 
Altered behaviour has been observed in Rln3 mutant mice (Table 1.1), including 
behaviours such as feeding and the motivational aspects of feeding, anxiety, 
arousal, and locomotion, although described phenotypes were inconsistent 
between studies due to differences in background strain and other unknown 
factors. In the studies described in this chapter, the effects of mutations in the 
rln3a locus on stress and anxiety behaviours and body weight were tested in 
zebrafish. 
 
One of the main features of RLN3 neurons is their activation in response to 
stress, which increases in RLN3 levels in rats (Banerjee et al. 2010, Tanaka et al. 
2005, Watanabe et al. 2011a). As this response is dependent on CRF1 
receptors, which are also implicated in anxiety behaviours in rats and humans 
(Hauger et al. 2009, Risbrough & Stein 2006), the loss of RLN3 may lead to 
altered anxiety levels. 
 
Zebrafish have robust stress responses, and there are established methods for 
studying stress and anxiety in zebrafish (Cachat et al. 2010, Egan et al. 2009, 
Maximino et al. 2010). A number of manipulations have been demonstrated to be 
stressful for fish, including restraint, temperature, social isolation, predator 
exposure, crowding, chasing with a net and low tank water levels (Piato et al. 
2011). Pharmacological agents can also alter zebrafish stress and anxiety 
behaviours, with fluoxetine and ethanol acting as anxiolytic agents; and caffeine 
and the alarm pheromone as anxiogenic agents (Cachat et al. 2010). The ‘novel 
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tank diving’ assay is a common method of testing anxiety in zebrafish, which 
quantifies exploratory behaviour in a novel space, and is likened to the large open 
field test for rodents. As the name suggests, zebrafish have an initial diving 
response to a novel tank for 70%–80% of the first minute (Gerlai et al. 2000, 
Levin et al. 2007), after which they begin to explore the tank. The tank is divided 
into the top and bottom halves, where fish would exhibit a chance level of being in 
either half after the first minute. Behaviours that reflect increased anxiety include 
increased latency to enter the top half of the tank, percentage time spent at the 
bottom, distance travelled at the bottom, number of erratic movements and 
number and frequency of freezing bouts (Cachat et al. 2010).  
 
A behaviour that can be used to test dark-evoked responses is the visual motor 
response, where larval zebrafish display robust and distinctive patterns of 
increased and decreased locomotor activity according to alternating periods of 
light and darkness (Emran et al. 2008). At the transition from light to dark, the 
decrease in illumination triggers immediate extended swimming before activity 
levels decrease, while increased light causes a startle followed by transient 
freezing, before activity levels increase. Larval zebrafish are known to exhibit 
dark avoidance in a light-dark box, where dark stimuli appear to be aversive 
(Cheng et al. 2016, Colwill & Creton 2011). Hence, the visual motor response 
could be interpreted as stress-induced behavioural activation and has been used 
to test experience-dependent modulation of fear responses when exposed to 
repeated cycles of light OFF and light ON (Agetsuma et al. 2010). In this study, 
larvae with lesioned dorsal lateral habenula (dHbL) continued to have extended 
locomotion 14–24 min after the dark stimulus and did not reduce activity after 
multiple cycles as quickly as intact fish. In line with dorsal habenula’s proposed 
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function of coping with stressors (Hsu et al. 2014, Lee et al. 2010), modified 
behaviour in lesioned fish was interpreted as an inability to regulate fear 
responses associated with the aversive light OFF stimulus despite multiple 
exposures to it. The PAG and NI are proposed downstream targets of the dHbL in 
zebrafish via the interpeduncular nucleus (Okamoto et al. 2012), implying that 
Rln3 may be involved in this behaviour through this pathway.  
 
In our laboratory, calcium imaging of the zebrafish PAG revealed responses to 
light and dark stimuli (Figure 3.1A-E, unpublished data). Light ON did not have a 
consistent effect on PAG neurons, whilst light OFF consistently activated the 
lateral PAG, as indicated by a tonic rise in fluorescence of the genetically 
encoded calcium indicator GCaMP6f. There was no change to the activity of the 
NI in response to the light or dark stimuli. The dark-evoked activity occurred in the 
region of the PAG containing rln3a-expressing cells, as indicated by ISH (Figure 
3.1). This raises the possibility that Rln3a signalling in the PAG may have a role 
in behavioural responses to dark stimuli.  
 








Figure 3.1 Two-photon calcium imaging of evoked activity in PAG. 
(A-D) Yellow arrows indicate the lateral PAG in a single 7 dpf fish expressing 
elavl3:GCaMP6f. Blue pixels superimposed correspond to onset (A) and offset 
(B) of blue light and red pixels correspond to onset (C) and offset (D) of red light. 
The PAG responds only to offset of light. (E) Temporal traces obtained from the 
PAG to multiple pulses of light are shown in grey. Each grey trace comes from a 
single fish (n = 12). Black trace shows the average. Fluorescence increases in 
the PAG can only be seen when the light is switched off. Onset of light is 
indicated by a vertical black line and offset is indicated by dashed black line. 
Coloured wedges indicate the wavelength of light presented. ∆F/F is obtained by 
subtracting and dividing the raw fluorescence trace by its average.  Scale bar = 
25 μm. (F) rln3a is expressed in the PAG and in the NI in zebrafish. ISH, showing 
the location of rln3a-expressing cells in the PAG (yellow arrows) and NI (cyan 
arrow) in a 4 dpf fish. Figure kindly provided by Ruey-Kuang Cheng, Suresh 
Jesuthasan and Seetha Krishnan. 
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Although most of the literature on RLN3 has attributed functions of this peptide to 
expression in the NI, the PAG is involved in functions that have been ascribed to 
RLN3. The PAG has historically been identified as mediating defensive 
behaviours (Bandler & Depaulis 1991, De Oca et al. 1998, Fanselow 1991, 
Tovote et al. 2016) and has other roles in pain processing, vocalisation and 
autonomic regulation (Behbehani 1995). The columnar organisation within the 
PAG segregates defence circuits into opposing categories, where the 
ventrolateral unit is associated with quiescence and the lateral subunit controls 
defensive behaviours (Bandler & Shipley 1994). Notably, a study by Blasiak et al. 
(2013) demonstrated that the RLN3-producing neurons in the ventral and lateral 
portions of the PAG in rats innervates the intergeniculate leaflet, suggesting a 
role in circadian functions, sleep/arousal and visuomotor systems (Horowitz et al. 
2004, Morin & Blanchard 2005). Furthermore, RLN3 null mutant mice exhibited 
reduced activity according to the circadian cycle (Smith et al. 2012), implying that 
this arousal function of RLN3 might be mediated by the PAG.  
 
Hence, in addition to testing rln3asq4sj-/- mutants for RLN3-associated behaviours 
such as feeding and anxiety, the visual motor response assay was used to 
determine if Rln3a is involved in a response to darkness. 




Danio rerio AB strain was used as the WT strain for all behaviour assays 
conducted in these studies. Embryos were grown in an incubator at 28 °C for 3–5 
days before being transferred to a facility with a 14 h light, 10 h dark cycle. Adult 
fish were fed three times daily with a mixture of fish flakes and brine shrimp. 
 
3.2.2 Assessment of zebrafish feeding 
Zebrafish embryos are grown in groups of 50 per petri dish in 35 mL of E3 (egg 
water, 5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4) in a dark 
incubator at 28 °C unfed, as they posses yolk stores. At 3 dpf, hatched larvae are 
relocated to the hatchery and grown in batches of 50 in 500 mL of E3, where they 
are subjected to a 14 h day, 10 h night cycle and fed with spirulina (dried algae). 
At about 10 dpf, fish were transferred into 3 L tanks in groups of 20 fish per tank, 
as fish density greatly affects body size. Measurements were taken at the 
juvenile stage, once per week at 5–7 weeks post fertilisation, as fish size starts to 
become most variable at this age. Fish were anesthetised in 1 x MS222 (0.4 g/L 
tricaine methanesulfonate, Sigma-Aldrich) before being measured for body 
weight and length, and then returned to their home tanks for further 
measurements to be taken in the following week. 
 
3.2.3 Novel tank diving assay 
Adult zebrafish (3.5 months old) were tested for anxiety using the novel tank 
diving assay. Fish were video tracked over a 5 min duration in a tank measuring 
20 cm x 12 cm x 5 cm (L x W x H) containing 1 L of water. For a baseline 
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measurement of anxiety, fish were netted from their home tanks into a container 
for transport to the tank setup, before transferring into the test tanks as quickly as 
possible to minimise handling stress. An independent group of fish from the same 
home tank was subjected to mild restraint stress in a 100 mL beaker filled with 10 
mL of water for 10 min, before testing in the novel tank. Fish were tested between 
1 p.m.–5 p.m. to reduce the variation due to circadian effects. Percentage of time 
spent at the bottom half of the tank is used as a measure of anxiety, as the fish 
would spend less time exploring the top half if they are more anxious (Cachat et 
al. 2010). Additionally, locomotion in the novel tank was also measured.  
 
3.2.4 Visual motor assay 
Zebrafish embryos were grown as in section 3.2.2, where embryo/larval density 
was important for obtaining consistent behaviour. 7–14 dpf larvae were placed 
into 24- or 48-well plate filled with 2 or 1 mL of E3 respectively, using water from 
their home tank. After a 1 h habituation period in the light, six cycles of 30 
minutes light OFF, 30 minutes light ON was administered during the circadian 
day, beginning at 4 p.m. and ending at the beginning of the circadian night at 10 
p.m. 
 
The behavioural setup was placed in an enclosed box with two light sources that 
controlled illumination from the bottom of the plate, using a light pad (Artograph) 
to control light stimuli, as well as four infra-red LED light bars for the video 
tracking. A translucent acrylic sheet was used to both diffuse the light source for 
even lighting to the camera, and to reduce heat to the plate, where the 
temperature did not exceed 28.5 °C. A camera was placed overhead to track 
zebrafish locomotion at 5 frames per second, using a custom written program. 
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Data was exported as images and x-y coordinates every 20 min, and analysed by 
a custom-written macro on Microsoft Excel, where the threshold for inactivity was 
considered to be 1 s/min. Activity per minute was converted into distance 
travelled, which was used for plotting locomotion (mm/min) over time. 
 
3.2.5 qRT-PCR 
qRT-PR was conducted as described in 2.2.3.3. Additional gene specific primers 
are for rln3b and rxfp3.2b are listed in Table 3.1. As the rxfp3.2b gene had no 
introns, DNAse treatment from the RNAqueous®-Micro Kit (ThermoFisher) was 




Statistical analyses were performed using R (https://www.r-project.org). Shapiro-
Wilk test was used to determine if samples were not different from the normal 
distribution under the null hypothesis. If the null hypothesis was accepted, 
samples were considered as normally distributed, and the mean (M) and 95% 
confidence intervals (95% CI) were reported. Welch’s t-test for unequal variances 
was used to compare between two groups, with effect size calculated as Cohen’s 
Table 3.1 List of primers for qRT-PCR 
Gene Primer (5’ !  3’) Amplicon size 
rln3b F CTGCGGGAGAGAGTTCATCC 172 bp 
 R ACGGGGTCTGTATGATAGTCCA  
rxfp3.2b F TTGTCCTAACCCTGCCGTTC 188 bp 
 R GCGACTGTGCATCTTCAACG  
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d. If the null-hypothesis of the Shapiro-Wilk test was rejected, samples were 
considered as non-normally distributed, and the median (Mdn) and the 
interquartile range (IQR) were reported. The Mann-Whitney test was used as a 
nonparametric test, and effect size was reported as r (Z / √N, where Z is the z-
statistic and N is the total sample size). If one of the groups being compared was 
not normally distributed, nonparametric tests were used as a conservative 
approach. All tests were conducted at a significance level of 0.05. p-values were 
indicated as *p < .05, **p < .01, ***p < .001. 
 
Graphical representations of the data employed boxplots to represent group 
distributions, where centrelines indicate medians, and box limits indicate 25th and 
75th percentiles with Tukey-style whiskers extending 1.5 times the IQR. Outliers 
are defined as data points that lie outside the whiskers of the boxplot (Tukey 
1977). The mean of each group is represented by a cross symbol, and all error 
bars are shown as 95% CIs around the mean, as recommended by Krzywinski & 
Altman (2013). Sample points are plotted as unfilled circles, while filled circles 
represent outliers.  
CHAPTER 3 – BEHAVIOURAL PHENOTYPING OF RLN3A MUTANTS  
67 
3.3 Results 
3.3.1 Effects of mutation in rln3a on stress and anxiety 
rln3asq4sj-/- mutants and WT siblings were placed in a novel tank for five minutes, 
both under baseline conditions (unstressed) and after being stressed by being 
placed in an isolated beaker with shallow water for ten minutes. 
 
In the novel tank diving assay, anxious fish would preferentially dwell in the 
bottom half of the tank (Egan et al. 2009). The total time spent in the bottom half 
of the tank during the non-stress condition were similar in rln3asq4sj-/- mutants (M = 
44.1%, 95% CI [35.2, 53.0]) and WT siblings (M = 50.2%, 95% CI [42.2, 58.2]) 
over the entire duration of the assay; this was also the case under stress 
conditions (WT sibling, M = 53.9%, 95% CI [50.0, 57.8]; rln3asq4sj-/- mutants, M = 
52.0%, 95% CI [40.9, 63.2]) (Figure 3.2A). However, in the stress condition, the 
distribution for the mutants was much wider than that of the WTs, with some still 
spending less than 25% in the bottom half and two fish remaining at the bottom 
for the entire duration. This implied that the mutants were more sensitive to the 
stress condition, where two fish displayed high levels of anxiety as compared to 
WT. A 2x2 analysis of variance (ANOVA) with genotype (WT sibling, rln3asq4sj-/-) 
and condition (stress, non-stress) revealed no main effects in genotype [F(1, 76) 
= 0.98, p = .33, η2 = .012], condition [F(1,76) = 2.09, p = .15, η2 = .026] or 
interaction between genotype and condition [F(1,76) = 0.28, p = .60, η2 = .003] for 
the time spent at the bottom of the tank.  
 
Locomotion in the novel tank was also quantified, where the total distance 
travelled by the rln3asq4sj-/- mutants (M = 9.71 m, 95% CI [8.86, 10.6]) and WT 
siblings (M = 10.4 m, 95% CI [9.79, 11.0]) were similar in the non-stress 
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condition, but rln3asq4sj-/- mutants (M = 8.04 m, 95% CI [7.20, 8.90]) had reduced 
locomotion compared to WT siblings (M = 9.44 m, 95% CI [8.85, 10.0]) under the 
stress condition (Figure 3.2B). Using a 2x2 ANOVA, both genotype [F(1,76) = 
8.92, p = .004**, η2 = .089] and condition [F(1,76) = 14.1, p < .001***, η2 = .14] 
displayed main effects, while there was no main effect for the interaction [F(1,76) 
= 0.98, p = .33, η2 = .010]. Tukey’s post hoc test was used to conduct pairwise 
comparisons between groups, with Cohen’s d used as a measure of effect size, 
as reported in Figure 3.2B. These comparisons revealed reduced locomotion in 
mutants compared to WT siblings in the stress condition, and also a decrease in 
distance travelled during the stress condition compared to the non-strss condition 
in the rln3asq4sj-/- mutants, which was not observed in the WT sibling group. This 
could indicate an increased pausing and freezing episodes in rln3asq4sj-/- mutants 
under stress conditions, showing increased sensitivity to stress compared to WT 
siblings. 
 
The percentage of time spent at the bottom of the tank was analysed by minute 
during non-stress (Figure 3.2C) and stress (Figure 3.2D) conditions, as zebrafish 
tend to display novelty-induced anxiety-like behaviour in the first minute. In the 
non-stress condition, there was a main effect of time [F(4, 152) = 3.09, p = .024*, 
η2 = .024] and the interaction of time and genotype [F(4, 152) = 4.06, p = .006**, 
η2 = .032] but not genotype [F(1, 38) = 1.05, p = .31, η2 = .019] (two-way repeated 
measures ANOVA). Violations to Mauchly's test for sphericity were subjected to 
Huynd-Feldt corrections. Welch’s t-test was used to compare percentage time 
spent at the bottom between the two genotypes in each minute during the non-
stress condition, where rln3asq4sj-/- mutants spent less time in the bottom half of 
the tank compared to WT siblings only in the first minute (Table 3.2).  
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In the stress condition, two-way repeated measures ANOVA with Huynd-Feldt 
corrections only revealed a main effect of time [F(4, 152) = 4.70, p = .002**, 
η2 = .045], but not genotype [F(1, 38) = 0.20, p =  .66, η2 = .003] or the interaction 
[F(4, 152) = 1.06, p  = .38, η2 = .010]. No difference was found in time spent in 
the bottom half of the tank between WT siblings and rln3asq4sj-/- mutants using 
Welch’s t-test (Table 3.2). This implies that rln3asq4sj-/- mutants had mildly reduced 
baseline anxiety levels compared to WT siblings in the first minute of exposure to 
a novel environment, but no differences in anxiety levels were found under stress 
conditions. 
  





Figure 3.2 Stress and anxiety behaviours in rln3asq4sj-/- mutants 
rln3asq4sj-/-mutant and WT sibling fish were assayed for anxiety behaviours using 
the novel tank assay under both non-stress and stress conditions. (A) Both 
groups spent a similar percentage of time in the bottom half of the tank 
throughout the entire test. (B) rln3asq4sj-/-  mutants had reduced locomotion after 
stress, whereas WT siblings did not. After stress, distance travelled for rln3asq4sj-/- 
mutants was also reduced compared to WT siblings. Percentage of time spent in 
the bottom half was analysed by minute, in the non-stress (C) and stress (D) 
conditions. WT siblings displayed increased bottom dwelling time only in the first 
minute of the non-stress condition. Crosses represent mean and error bars 
represent 95% confidence intervals, individual fish measurements were plotted 
as unfilled circles and outliers as filled circles. (B) p values reported from Tukey’s 
post hoc test following 2x2 ANOVA. (C) and (D) p values reported from Welch’s t-
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Table 3.2 Statistical analysis of time spent in the bottom half (%) during 
the novel tank diving assay 
Non-stress 
Minute WT sibling rln3asq4sj-/- mutant p value d 
1 53.3 ±"12.6 37.3 ±"10.0 t(36.2) = 2.09, p = .044* 0.66 
2 49.3 ±"9.8 39.6 ±"10.9 t(37.6) = 1.39, p = .17 0.44 
3 49.7 ±"7.5 39.6 ±"10.0 t(35.3) = 1.69, p = .10 0.53 
4 46.6 ±"8.3 49.5 ±"11.2 t(35.2) = 0.43, p = .67 0.14 
5 51.6 ±"9.4 55.1 ±"11.6 t(36.4) = 0.50, p = .63 0.15 
 
Stress 
Minute WT sibling rln3asq4sj-/- mutant p value d 
1 44.7 ±"7.0 44.9 ±"15.0 t(27.0) = 0.036, p = .97 0.011 
2 53.4 ±"7.2 50.8 ±"13.1 t(29.6) = 0.36, p = .72 0.11 
3 60.4 ±"9.0 50.5 ±"12.4 t(34.6) = 1.36, p = .18 0.43 
4 59.9 ±"1.0 56.2 ±"10.8 t(32.6) = 0.59, p = .56 0.19 
5 54.7 ±"8.1 58.1 ±"11.1 t(34.8) = 0.52, p = .61 0.16 
Values are means ±"95% CI. *p < 0.05. n = 20 in each group. 
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3.3.2 Effects of mutation in rln3a on the visual motor response 
The visual motor response of rln3asq4sj-/- mutants and WT siblings was compared 
to test if mutants exhibit an enhanced fear response, like dHbL-lesioned fish, 
where increased locomotion was observed in lesioned fish in minute 14–24 of the 
dark period compared to intact fish (Agetsuma et al. 2010). The analysis method 
of Agetsuma et al. (2010) was used to enable a direct comparison with this study. 
Some amendments to the analyses include testing for normality before applying 
hypothesis testing, as described in section 3.2.6, reporting effect sizes, plotting 
95% CI as error bars, and including box plots and individual data points in the 
graphical representation for better visualisation of the responses. 
 
Traces of locomotor activity during six repeated cycles of dark and light stimuli 
were similar in rln3asq4sj-/- mutants and WT siblings (Figure 3.3A). A two-way 
repeated measures ANOVA of the entire dark cycle indicated no difference 
between the visual motor response in both groups, where the p value for the 
interaction between genotype and time for each cycle are as follows: Cycle 1, 
F(29, 1276) = 0.89, p = .49, η2 = .008; Cycle 2, F(29, 1276) = 0.80, p = .57, 
η2 = .007; Cycle 3, F(29, 1276) = 0.80, p = .54, η2 = .007; Cycle 4, 
F(29, 1276) = 0.33, p = .88, η2 = .004; Cycle 5, F(29, 1276) = 0.46, p = .73, 
η2 = .006; Cycle 6, F(29, 1276) = 0.41, p = .77, η2 = .007. 
 
When comparing locomotor activity in the first 10 minutes of the dark period, 
rln3asq4sj-/- mutants were less active in the first cycle (Figure 3.3B). No differences 
were observed in minute 14–24 of the dark period (Figure 3.3C), or in the entire 
light period (Figure 3.3D. For more details, see Table 3.3). Hence, the behaviour 
of rln3asq4sj-/- mutants did not phenocopy fish with dHbL lesions. 




1st cycle 2nd cycle 3rd cycle

























0 10 20 30 40 50 60 0 10 20 30 40 50 60 0 10 20 30 40 50 60













First 10 minutes of dark period













1 2 3 4 5 6
1 2 3 4 5 6







































p = .49 p = .57 p = .54















































Figure 3.3 Visual motor response of rln3asq4sj-/- mutants 
 (A) Charts illustrating locomotor activity over 6 cycles of dark (black bars) and 
light (white bars), with each cycle lasting 1 h. Error bars show 95% CI. p value 
from the interaction term (Genotype x Time) of two-way repeated measures 
ANOVA against the entire dark period. Total locomotor activity was assessed 
every cycle in the first 10 minute (B) and from minute 14-24 (C) of the dark 
period, as well as the whole light period. (D) Locomotor activity of rln3asq4sj-/- 
mutants was only decreased in the first cycle of (B). (B-D) Crosses represent 
mean and error bars represent 95% CI, individual larval measurements were 
plotted as unfilled circles. For data satisfying normality criteria by the Shapiro-
Wilk test, p values were reported from Welch’s t-test, effect size as Cohen’s d. 
Otherwise, p value were reported from Mann-Whitney test, r reported as non-
parametric effect size. 
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Table 3.3 Statistical analysis of locomotor activity in the visual motor response of rln3asq4sj-/- mutants 
First 10 minutes 
Cycle 
Total locomotor activity (mm) 
p value Effect size WT sibling rln3asq4sj-/- mutant 
1 M = 2285, 95% CI [2088, 2481] M = 1881, 95% CI [1625, 2137] t(39.4) = 2.60, p = .013* d = 0.78 
2 M = 2326, 95% CI [2065, 2586] M = 1996, 95% CI [1777, 2215] t(43.6) = 2.01, p = .051 d = 0.58 
3 M = 2043, 95% CI [1763, 2323] M = 1891, 95% CI [1637, 2145] t(44.0) = 0.83, p = .41 d = 0.24 
4 M = 1779, 95% CI [1509, 2050] M = 1574, 95% CI [1308, 1840] t(43.8) = 1.12, p = .27 d = 0.33 
5 M = 1575, 95% CI [1315, 1835] M = 1505, 95% CI [1256, 1754] t(43.9) = 0.41, p = .69 d = 0.12 
6 M = 1434, 95% CI [1221, 1647] M = 1319, 95% CI [1061, 1578] t(40.9) = 0.71, p = .48 d = 0.21 
Minute 14–24 
Cycle 
Total locomotor activity (mm) 
p value Effect size WT sibling rln3asq4sj-/- mutant 
1 Mdn = 1259, IQR [627, 2075] Mdn = 1020, IQR [594, 1258] W = 307, p = .34 r = .14 
2 Mdn = 956, IQR [353, 1670] Mdn = 679, IQR [297, 1277] W = 319, p = .22 r = .18 
3 Mdn = 459, IQR [192, 1190] Mdn = 296, IQR [171, 556] W = 290, p = .56 r = .089 
4 Mdn = 221, IQR [100, 497] Mdn = 141, IQR [98.8, 253] W = 319, p = .22 r = .18 
5 Mdn = 158, IQR [78.8, 250] Mdn = 131, IQR [118, 155] W = 294, p = .50 r = .10 
6 Mdn = 141, IQR [91.7, 196] Mdn = 103, IQR [71.5, 128] W = 335, p = .11 r = .23 
WT sibling n = 25,  rln3asq4sj-/- mutant n = 21. *p < 0.05. 
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Table 3.3 Statistical analysis of locomotor activity in the visual motor response of rln3asq4sj-/- mutants (continued) 
Whole light period 
 Total locomotor activity (mm)   
Cycle WT sibling rln3asq4sj-/- mutant p value Effect size 
1 M = 4798, 95% CI [3963, 5634] M = 4484, 95% CI [3453, 5515] t(40.6) = 0.49, p = .63 d = 0.15 
2 M = 3907, 95% CI [3224, 4591] M = 3793, 95% CI [3043, 4543] t(42.7) = 0.23, p = .82 d = 0.069 
3 Mdn = 2941, IQR [2693, 3408] Mdn = 2679, IQR [2289, 3857] W = 310, p = .30 r = .15 
4 Mdn = 2404, IQR [1726, 3407] Mdn = 2644, IQR [1618, 3534] W = 265, p = .97 r = .008 
5 Mdn = 1543, IQR [1080, 2501] Mdn = 1739, IQR [935, 3485] W = 262, p = 1.00 r = .002 
6 Mdn = 1541, IQR [786, 2240] Mdn = 1296, IQR [734, 2579] W = 283, p = .66 r = .067 
WT sibling n = 25, rln3asq4sj-/- mutant n = 21. *p < 0.05. 
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3.3.3 Effects of mutation in rln3a on body weight and length 
As stress affects food intake (Timofeeva et al. 2016), and RLN3 signalling is 
associated with changes in feeding behaviour (Calvez et al. 2016a,b; Ganella et 
al. 2012, Hida et al. 2006, Lenglos et al. 2014a, McGowan et al. 2005, 2006), 
juvenile rln3asq4sj-/- mutants and WT siblings were measured for body length and 
weight at 5–7 weeks post fertilisation.  Across all time periods, body length and 
remained similar in both groups. At week 5: WT sibling, Mdn = 15.0 mm, 
IQR [13.0, 17.0]; rln3asq4sj-/- mutant, Mdn = 14.0 mm, IQR [12.0, 15.0]; W = 287, 
p = .092, r = .26, Mann-Whitney test. At week 6: WT sibling, Mdn = 18.0 mm, 
IQR [15.8, 19.0]; rln3asq4sj-/- mutant, Mdn = 16.5 mm, IQR [15.0, 19.3]; W = 201, 
p = .54, r = .10, Mann-Whitney test. At week 7: WT sibling, M = 21.6 mm, 
95% CI [20.0, 23.2]; rln3asq4sj-/- mutant, M = 19.9 mm, 95% CI [18.5, 21.4]; 
t(33.9) = 1.66, p = .11, d = 0.55, Welch’s t-test (Figure 3.4A). 
 
Body weights of rln3asq4sj-/- mutants and WT siblings were also similar, with the 
exception of week 5, where rln3asq4sj-/- mutants (M = 23.9 mg, 
95% CI [18.0, 29.8]) weighed less than WT siblings (M = 34.8 mg, 
95% CI [27.9, 41.7]), t(39.0) = 2.5, p = .017*, d = 0.77, Welch’s t-test. At week 6: 
WT sibling, M = 57.7 mg, 95% CI [45.9, 69.5]; rln3asq4sj-/- mutant, M = 51.6 mg, 
95% CI [38.5, 64.7]; t(35.2) = 0.73, p = .47, d = 0.24, Welch’s t-test. At week 7: 
WT sibling, M = 112 mg, 95% CI [89.6, 135]; rln3asq4sj-/- mutant, M = 94.3 mg, 
95% CI [71.6, 117]; t(33.9) = 1.18, p = .24, d = 0.39, Welch’s t-test (Figure 3.4B).  
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Figure 3.4 Body weight and length in rln3asq4sj-/- mutants 
Body length (A) and body weight (B) of rln3asq4sj-/- mutants was similar to that of 
WT sibling at 5, 6, and 7 weeks post fertilisation, with the exception of body 
weight at week 5. Sample sizes varied per week due to fish deaths. Week 5: WT 
sibling n=21, rln3asq4sj-/- mutant n=21. Week 6:  WT sibling n=20, rln3asq4sj-/- 
mutant n=18. Week 7: WT sibling n=19, rln3asq4sj-/- mutant n=17. Means were 
plotted as crosses and error bar represent 95% confidence intervals. Individual 
fish were plotted as unfilled circles, with outliers plotted as filled circles. For data 
satisfying normality criteria by the Shapiro-Wilk test, p values were reported from 
Welch’s t-test, effect size as Cohen’s d. Otherwise, p value were reported from 
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3.3.4 Quantitative expression of rln3a-related genes 
One explanation for a lack of a distinct behavioural phenotype in the rln3asq4sj-/- 
mutants as compared to WT sibling controls is that there are compensatory 
effects from other genes. In light of the multiple duplicated genes in the zebrafish 
genome, possible candidates to compensate for a lack of rln3a would be its 
paralogue, rln3b, and its receptor, rxfp3.2b. Hence, qRT-PCR was used to check 
if the expression of these genes were altered in the mutants. 
 
Whole adult fish brains (n=10) from rln3asq4sj-/- mutants and WT siblings were 
analysed for rln3b and rxfp3.2b expression using qRT-PCR. After verifying that 
primers were sufficiently efficient at 98.9% and 99.7% for rln3b and rxfp3.2b 
respectively, the 2-∆∆Ct method (Livak & Schmittgen 2001) was used for analysis 
(Figure 3.5B, D). The melt curve displayed a single peak for all amplicons (Figure 
3.5C, E), while PCR products presented single bands when visualised on 
agarose gel (Figure 3.5A), indicating specificity. No genomic contamination was 
detected in the negative control without reverse transcriptase.  
 
The expression levels of rln3b were upregulated approximately four-fold in the 
rln3asq4sj-/- mutants (∆Ct M = -9.88, 95% CI [-10.3, -9.47]) compared to WT 
siblings (∆Ct M = -8.28, 95% CI [-8.81, -7.75]) (Figure 3.5F, G). rln3b could not be 
detected in two rln3asq4sj-/- mutant fish, and these samples were omitted from the 
analysis. Additionally, rxfp3.2b expression in the rln3asq4sj-/- mutant (∆Ct 
M = -9.43, 95% CI [-10.5, -8.36]) was similar to WT siblings (∆Ct M = -8.98, 
95% CI [-9.75, -8.21]) (Figure 3.5H, I). This indicates a possible partial 
compensation of rln3b gene as a result of the mutagenesis. 
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Figure 3.5 qRT-PCR analyses of rln3a related genes 
(A) qRT-PCR products present a single band on agarose gel, with no 
amplification in the RT– control.  (B-E) Optimisation of primers. Standard curves 
indicate close to 100% efficiency for all primers used (B, D). Melt curves display a 
single peak, indicating specificity of primers to the amplification product (C, E). 
The expression levels of rln3b and rxfp3.2b were compared in WT sibling and 
rln3asq4sj-/- fish (n = 10 per group). (F, H) Normalised difference in threshold cycles 
(∆Ct = Ctref – Ctgene). Individual fish samples were plotted as unfilled circles, 
crosses represent mean and error bars represent 95% confidence interval of the 
mean. As two samples from mutant fish failed to produce amplification products 
with rln3b primers, they were removed from the analysis in F and G. (G, I) Fold 
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3.4 Discussion 
3.4.1 Comparison of zebrafish rln3asq4sj-/- mutant with rodent studies 
RLN3 signalling has been implicated as a regulator of stress and anxiety related 
behaviours in multiple studies involving drug-induced activation or inhibition of 
RXFP3 in rats (Ryan et al. 2013a, Zhang et al. 2015). However, mouse Rln3 loss-
of-function mutants do not display strong phenotypes, where mutants have been 
reported to be mildly hypersensitive to stress (Smith et al. 2009), slightly less 
anxious than controls (Watanabe et al. 2011b). In a separate study, mouse 
mutants behaved similarly to WT littermates under baseline conditions or after 
being chronically stressed (Smith et al. 2012). In Rxfp3 null mutant mice, only a 
mild and inconsistent decrease in anxiety was observed in multiple tests (Hosken 
et al. 2015). Similarly, zebrafish rln3asq4sj-/- mutants only displayed a mild 
decrease in anxiety or hypersensitivity to stress. Under baseline (low) levels of 
anxiety, rln3asq4sj-/- mutants appeared less susceptible to novelty-induced stress 
compared to WT siblings, as they displayed a reduced percentage of time spent 
at the bottom of the tank in the initial minute of the novel tank diving assay. At the 
same time, a mild stressor elicited a decrease in locomotion in rln3asq4sj-/- mutants 
but not in WT siblings, which can be interpreted as increased sensitivity to stress 
in mutants. However, there was quite a high level of individual variation in both 
groups of fish to show a convincing effect. The effects may be too small to be 
detected by the current sample size, or the stressor may be too mild.  
 
Initial studies of the effects of central administration of RLN3 on rodent behaviour 
suggested roles in feeding, with increased feeding upon i.c.v. injection of RLN3 
(McGowan et al. 2005, 2006). However, in studies using Rln3 mutant mice, only 
one report identified a possible effect with similar decreased body weight in 
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mutants fed a high fat diet (Sutton et al. 2009), while others found no differences 
in body weight between mutant and WT mice (Smith et al. 2009, 2012; Watanabe 
et al. 2011b). These contradictory reports were attributed to the fact that mixed 
background mutants were used, which would inherit an undetermined selection of 
genes from either genetic background that could affect the behaviour of these 
groups (Smith et al. 2012). Consistent with the latter reports, body weight and 
length measurements for zebrafish rln3asq4sj-/- mutants were largely similar to WT 
siblings. 
 
Overall, a comparison between RLN3/Rln3a-related behaviours tested using null 
mutations in mouse and zebrafish is summarised in Figure 3.6. 
 
 
Figure 3.6 Comparison of the effects of RLN3/Rln3a null mutation on 
mouse and zebrafish behaviours 
Summary of behavioural effects of a loss of RLN3 in mouse from various studies, 
compared to the loss of Rln3a in zebrafish from the studies conducted in this 
thesis. In particular, stress and anxiety behaviours and body weight was 
compared.  
↓ body weight 
(Sutton et al., 2009) ↓ body weight in (week 5)
No effect 
(Watanabe et al., 2011)
No effect (week 6 & 7)No effect (Smith et al., 2009)
No effect 
(Smith et al., 2012)














medication, SS affects a large proportion of the general
population and is becoming a major biomedical concern
[79]. Thus, there is a widely recognized need for novel
experimental models of SS [78,79]. Characteristic beha-
vioral, neuromuscular, and autonomic responses are
observed in rodents following administration of serotoner-
gic drugs, representing useful experimental models of SS
[78,80]. Exposed to serotonergic agents and their combina-
tions, zebrafish exhibit a characteristic top dwelling (sur-
facing behavior) and hypolocomotion, which positively
correlate with brain serotonin and may therefore represent
potential markers of SS-like states in zebrafish [79]. Thus,
the zebrafish seems to offer great promise for HTSs of novel
serotonergic drugs, probing the SS pathogenetic echan-
isms and the analysis of drug ! gene interactions [79].
Critical evaluation and future directions
Although there are many human brain disorders whose
modeling have been attempted, with some success, using
traditional laboratory species (e.g., rats or mice), the zebra-
fish appears to have an excellent future in this line of
research, and offers several important advantages. For
example, genetic factors play a key role in the pathogenesis
of brain disorders [81–84], and the utility of experimental
models in clinical neuroscience relies on the applicability of
the model to genetics research. Box 2 summarizes recent
successes in applyi g molecular genetics to zebrafish neu-
roscience research.
The relatively sophisticated zebrafish behavioral reper-
toire [85], including its highly social nature and the fact
that it is a diurnal species that relies heavily on vision (the
same modality humans use most), make it an excellent tool
for investigators interested in the analysis of brain func-
tion and dysfunction. In addition to the genetic tools
available for the zebrafish (Box 2) [5], transgenic zebrafish
fluorescence-based screens and optogenetic models enable
visualization of biological processes in the body, and an
unprecedented dissection of circuitry and cellular mechan-
isms of brain disorders [86,87].
Table 3. Documented sensitivity of zebrafish models to major
classes of neurotropic drugs
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Serotonergic drugs
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Logarithmic dose range
TRENDS in Pharmacological Sciences 
Figure 4. Comparative analysis of relative potencies of effective acute behavioral doses of selected psychotropic drugs in zebrafish and other species. Panel (A) shows
glutamatergic antagonists dizocilpine (MK801), phencyclidine (PCP), ibogaine (Ibo), ketamine (Ket), and kynurenic acid (KYNA); ‘normalized’ logarithmic dose range is 0.1–
20 mg/l for zebrafish [182], 0.05–200 mg/kg for mice, 0.003–25 mg/kg for non-human primates, and 0.01–15 mg/kg for humans [183]. *Data for KYNA not available. Panel (B)
shows zebrafish and human data for selected serotonergic drugs, including lysergic acid diethylamide (LSD), mescaline (Mes), psilocybin (Psi), and 3,4-
methylenedioxymethamphetamine (MDMA); ‘normalized’ logarithmic dose range is 0.1–120 mg/l for zebrafish and 0.0001–4 mg/kg for humans [184]. Collectively, these
data show similar ranking of the activity of drugs across various species, illustrating translational value of zebrafish models for screening clinically active neurotropic drugs.
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Hypersensitive to stress 
(Smith et al., 2009) Locomotion sensitive to stress
Slight ↓ anxiety 
(Watanabe et al., 2011) Slight ↓ anxiety to novel stimulus
No effect 
(Smith et al., 2012) No effect otherwise
Mouse Zebrafish
CHAPTER 3 – BEHAVIOURAL PHENOTYPING OF RLN3A MUTANTS  
83 
3.4.2 Involvement of Rln3a in the visual motor response 
The visual motor response was used previously to test enhanced fear responses 
in zebrafish with dHbL lesions, which reduces the capability of zebrafish larvae to 
cope with stress (Agetsuma et al. 2010). As the dHbL projects to the PAG and NI, 
Rln3 may be acting downstream of the habenula (Okamoto et al. 2012), in line 
with its production in response to stress. Calcium imaging indicates that the PAG 
is activated by dark stimuli but not the NI, suggesting a possible involvement of 
the Rln3 population in the PAG in modulating fear responses to dark stimuli. 
However, rln3asq4sj-/- mutants showed similar levels of activity to WT siblings, and 
only had decreased in activity in the initial presentation of dark stimuli, which 
could be interpreted as reduced responsiveness to stressful stimuli. Although 
these data indicate that the loss of Rln3a does not have similar effects to dHbL 
lesions, this is not surprising as the habenula regulates multiple other 
neuropeptides (Stephenson-Jones et al. 2012), and potentially the loss of one 
peptide might not modify behaviour significantly. 
 
3.4.3 Compensatory effects in genetic mutant models 
Compensatory effects are common in mutants, and as such there are no visible 
phenotypes. This is contrasted against knockdown approaches, such as 
morpholinos, that produce phenotypes when the same gene is targeted (Kok et 
al. 2015, Rossi et al. 2015). Despite the speculation that compensatory effects 
may be occurring, it is difficult to determine what might be compensating for the 
lack of Rln3. However, there are two possible levels of redundancies, one relates 
to the fact that different neuropeptide systems have similar functions, such as 
feeding and arousal. Another is teleost-specific whole genome duplication of 
genes. Compensation by Rln3a-related peptides in the mutant was tested by 
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measuring expression levels of rln3b and rxfp3.2b. Although the levels of the 
rln3a receptor, rxfp3.2b, remained the same, the paralogue rln3b was 
upregulated four-fold in mutants compared to wild types. This is a modest 
increase compared to the 16-fold decrease in rln3a expression, indicating that 
compensation by other genes is also likely. Nevertheless, this is the first report of 
the behavioural phenotyping of a Rln3a-deficient zebrafish line.  
CHAPTER 4 – BEHAVIOURAL EFFECTS OF A C-PEPTIDE POLYMORPHISM  
85 
4. BEHAVIOURAL EFFECTS OF A C-PEPTIDE POLYMORPHISM 
4.1 Introduction  
Unexpectedly, a SNP was found in the 158th position of the sequenced coding 
DNA sequence, where the WT C nucleotide was replaced by a T nucleotide 
(polymorphism abbreviated as c.158C>T) in the C-peptide (Figure 4.1). The 
studies described in this chapter explore the possibility that this SNP contributed 
to altered behaviour. 
 
 
The C-peptide, also called the connecting peptide, is cleaved from the propeptide 
of RLN3, with the remaining A- and B-chains forming mature RLN3 peptide. The 
A- and B-chains are highly conserved between mouse and human RLN3, with 
only two amino acid differences, compared to RLN which has 42% and 45% 
similarity in the A- and B-chains respectively (Bathgate et al. 2002). Within the 
RLN3 C-peptide, there is a surprisingly high conservation between mouse and 
human at 73%, compared with less than 20% in other RLNs (Bathgate et al. 
2002). This highlights the possibility of more conserved functionality of the RLN3 
 
Figure 4.1 SNP within the rln3a locus 
(A) Schematic representation of the Rln3a gene. Red box represents the 
receptor-binding motif; green box represents the genetic location of the SNP. (B) 
A SNP was found at position 158 of the cDNA with a single base pair change 
from C to T (c.158C>T). Predicted translation of the rln3ac.158C>T SNP variant 
reveals a non-synonymous substitution of the amino acid threonine to isoleucine 
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C-peptide compared to other family members in mammals (Bathgate et al. 2002). 
Inter-species variation in RLN3 C-peptide sequences makes alignment difficult 
(Wilkinson et al. 2005), as in the comparison of zebrafish Rln3 with mammalian 
forms in Figure 2.1, where the discrepancies in peptide sequence are large even 
when comparing zebrafish Rln3a and Rln3b. However, although the C-peptide in 
the related peptide, insulin, is not conserved, it is thought to have commonalities 
at a structural level that can assist in chaperone-like functions, self assembly, and 
protein interactions (Landreh & Jornvall 2015, Landreh et al. 2014). 
 
Although originally considered to be biologically inert, the C-peptide of insulin has 
been found to have bioactivity, although not directly related to insulin function of 
blood glucose regulation (Wahren et al. 2000, 2007). Instead, it has been linked 
with vascular, renal and neural dysfunctions in type I diabetics, where its 
administration is proposed for the treatment of such complications due to the lack 
of the C-peptide in patients (Ido et al. 1997, Wahren et al. 2007). However, in 
recent years, clinical evidence for the use of the insulin C-peptide has been 
controversial, where its efficacy is not clearly evident (Wahren & Larsson 2015). 
Within the RLN family, synthesis of two fragments of rat RLN C-peptide for 
assessment on the rat heart revealed no noticeable RLN-like activity (Dawson et 
al. 2001).  
 
Localisation of the RLN3 C-peptide in the rat brain has been carried out with the 
immunohistochemical detection of a conserved portion of the C-peptide in 
mammals (Brailoiu et al. 2009, Ma et al. 2007). The expression pattern of the 
RLN3 C-peptide using this method was largely similar to that of the A-chain of the 
mature peptide (Tanaka et al. 2005), being expressed in the NI, ventrolateral 
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PAG, and parts of the dorsal raphe and substantia nigra. Only some differences 
were detected in RLN3-like fibres, with low levels present in the olfactory bulbs 
and the cortex (Ma et al. 2007), and a lack of detection in the medial accessory 
nucleus of the inferior olive, which was densely labelled in anterograde tracing 
studies of the NI (Goto et al. 2001). Also, immunohistochemical staining was 
specific to the C-peptide of RLN3, as the antibody used did not recognise the 
mature peptide and could detect the same loci after pre-absorption with RLN3 
(Brailoiu et al. 2009).  
 
There is some evidence that the RLN3 C-peptide is neuroactive, modulating 
calcium levels and membrane potential in cultured rat hypothalamic neurons 
(Brailoiu et al. 2009). Using calcium dyes, distinct patterns of calcium activity 
were detected when cultured neurons were activated by RLN3 and its C-peptide, 
where the latter had sustained activity after an initial phasic response, while 
RLN3 only elicited an initial fast transitory response. These effects were 
modulated by differing sources of calcium, and could imply different roles for the 
two peptides (Brailoiu et al. 2009). Also, both RLN3 and its C-peptide are able to 
depolarise and hyperpolarise target neurons, as detected by voltage dyes 
(Brailoiu et al. 2009). Furthermore, competitive binding studies suggest that RLN3 
and its C-peptide activate different channels for their functions (Brailoiu et al. 
2009). However, there is currently no functional role for the RLN3 C-peptide 
identified in vivo. 
 
To investigate the effects of a rln3a C-peptide SNP on zebrafish behaviour, fish 
homozygous for the rln3ac.158T  allele were tested against fish homozygous for the 
rln3ac.158C  allele. This experiment was performed using two genetic backgrounds 
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within the AB WT strain, as background effects may interact with the 
polymorphism to generate a phenotype (Chandler et al. 2013). One concern was 
that the CRISPR mutagenesis could produce off target effects; hence one of the 
groups tested was WT siblings of the rln3asq4sj-/- mutants, which were obtained 
from incrossed heterozygous mutants (rln3asq4sj+/-), while the other was WT fish 
from the facility. 
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4.2 Results 
4.2.1 Sequencing of rln3a cDNA 
An SNP was detected in nucleotide 158 of the coding sequence of rln3a, 
consisting of the C and T nucleotide variants (Figure 4.1). All WT siblings of 
CRISPR-injected mutants possessed the rln3ac.158T allele (Figure 4.2A). Non-
sibling WT fish were sequenced to check if the WT polymorphism existed in the 
population. Out of four non-sibling WT fish sequenced, one was homozygous for 
the SNP (rln3ac.158T) and another was in the heterozygous form (shown as 
heterozygous form, rln3ac.158C/T, in Figure 4.2B). The rln3asq4sj-/- mutant fish 
possessed the WT variant of the SNP (c.158C=) (Figure 4.2C). In silico 
translation of the rln3ac.158T allele revealed a non-synonymous substitution from 
amino acid threonine to isoleucine, indicating that peptide function may be altered 





Figure 4.2 Sequencing of rln3a cDNA from WTs and rln3asq4sj-/- mutant 
(A) WT sibling of CRISPR-injected fish is homozygous for the SNP (rln3ac.158T). 
(B) Sequence from full-length cDNA of non-sibling WT fish, shown here as the 
heterozygous form of the SNP (rln3ac.158C/T). (C) The mutant rln3asq4sj-/- has a 7bp 
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4.2.2 Effects of C-peptide polymorphism on visual motor response 
The visual motor response was used to test if the SNP in the rln3a gene coding 
for the C-peptide would affect behaviour. In WT fish that were siblings of the 
rln3asq4sj-/- mutants, those with the rln3ac.158T allele were more active across the 
entire dark period (Cycle 3 and Cycle 4) compared to fish with the rln3ac.158C allele 
(Figure 4.3). A two-way repeated measures ANOVA was conducted for data from 
the entire dark cycle, where the p values (with Greenhouse-Geisser correction) 
for the interaction between genotype and time for each cycle are as follows: 
Cycle 1, F(29, 1247) = 0.89, p = .49, η2 = .008; Cycle 2, F(29, 1247) = 1.71, 
p = .12, η2 = .014; Cycle 3, F(29, 1247) = 1.40, p = .23, η2 = .011; Cycle 4, 
F(29,  1247) = 3.61, p = .003**, η2 = .034; Cycle 5, F(29, 1247) = 2.56, p = .040*, 
η2 = .034;  Cycle 6, F(29, 1247) = 1.27, p = .16, η2 = .021. When the visual motor 
response was analysed in separate time bins, the differences were seen mostly 
in the first 10 minutes of the dark period (Cycles 1, 2, 4, and 5), and the first cycle 
of the later part of the dark period (minute 14–24), but not during the light period 
(Table 4.1). 
 
In fish that were not siblings of the rln3a mutants, rln3ac.158T fish had similar 
locomotor activity compared to rln3ac.158C fish in the visual motor response 
(Figure 4.4). A two-way repeated measures ANOVA was conducted on data from 
the entire dark cycle, where the p value (with Greenhouse-Geisser correction) for 
the interaction between genotype and time for each cycle are as follows: Cycle 1, 
F(29, 1189) = 0.47, p = .88, η2 = .004; Cycle 2, F(29, 1189) = 1.04, p = .40, 
η2 = .009; Cycle 3, F(29, 1189) = 0.85, p = .56, η2 = .008; Cycle 4, 
F(29,  1189)  = 0.52, p = .79, η2 = .005; Cycle 5, F(29, 1189) = 1.07, p = .38, 
η2 = .011; Cycle 6, F(29,1189) = 1.63, p = .14, η2 = .016. When the visual motor 
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response was analysed in time bins, there was no difference in the activity of 
both groups of fish in the first 10 minutes of the dark cycle, unlike the WT siblings 
(Table 4.2). This implies that the c.158T polymorphism in the C-peptide causes 
WT fish to be more active, although how this modifies the visual motor response 
depends on the genetic background.  
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Figure 4.3 Visual motor response of rln3ac.158T and rln3ac.158C in WT siblings 
(A) Charts illustrating locomotor activity over 6 cycles of dark (black bars) and 
light (white bars), with each cycle lasting 1 h. Error bars show 95% CI. p value 
from the interaction term (Genotype x Time) of two-way repeated measures 
ANOVA against the entire dark period. Total locomotor activity was assessed 
every cycle in the first 10 minute (B) and from minute 14-24 (C) of the dark 
period, as well as the whole light period. (D) rln3ac.158T was hyperactive in 
selected cycles, within dark periods (B, C). (B-D) Crosses represent mean and 
error bars represent 95% CI, individual larval measurements were plotted as 
unfilled circles. For data satisfying normality criteria by the Shapiro-Wilk test, p 
values were reported from Welch’s t-test, effect size as Cohen’s d. Otherwise, p 
values were reported from Mann-Whitney test, r reported as non-parametric 
effect size.  
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Table 4.1 Statistical analysis of locomotor activity in the visual motor response of WT siblings 
First 10 minutes 
Cycle 
Total locomotor activity (mm) 
p value Effect size rln3ac.158C rln3ac.158T 
1 M = 2143, 95% CI [1846, 2440] M = 2639, 95% CI [2333, 2946] t(42.8) = 2.42, p = .020* d = 0.71 
2 M = 2036, 95% CI [1716, 2356] M = 2570, 95% CI [2255, 2885] t(42.4) = 2.48, p = .018* d = 0.73 
3 Mdn = 1818, IQR [1484, 2083] Mdn = 2191, IQR [1813, 2951] W = 174, p = .085 r = .26 
4 M = 1613, 95% CI [1309, 1918] M = 2104, 95% CI [1816, 2391] t(41.9) = 2.44, p = .019* d = 0.73 
5 Mdn = 1452, IQR [1164, 1704] Mdn = 1631, IQR [1431, 2216] W = 158, p = .036* r = .31 
6 Mdn = 1390, IQR [970, 1601] Mdn = 1300, IQR [1071, 1931] W = 213, p = .41 r = .13 
Minute 14–24 
Cycle 
Total locomotor activity (mm) 
p value Effect size rln3ac.158C rln3ac.158T 
1 Mdn = 695, IQR [365, 1497] Mdn = 1205, IQR [756, 2138] W = 162, p = .045* r = .30 
2 Mdn = 383, IQR [164, 946] Mdn = 739, IQR [389, 967] W = 171, p = .073 r = .27 
3 Mdn = 192, IQR [104, 390] Mdn = 303, IQR [136, 924] W = 205.5, p = .32 r = .15 
4 Mdn = 139, IQR [64, 268] Mdn = 133, IQR [76.4, 228] W = 255.5, p = .91 r = .019 
5 Mdn = 108, IQR [37.5, 137] Mdn = 64.3, IQR [41.5, 175] W = 253, p = .95 r = .10 
6 Mdn = 71.0, IQR [43.9, 114] Mdn = 76.1, IQR [37.7, 113] W = 244.5, p = .91 r = .019 
rln3ac.158C n = 20,  rln3ac.158T n = 25. *p < 0.05. 
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Table 4.1 Statistical analysis of locomotor activity in the visual motor response of WT siblings (continued) 
Whole light period 
 Total locomotor activity (mm)   
Cycle rln3ac.158C rln3ac.158T p value Effect size 
1 M = 3578, 95% CI [2449, 4707] M = 3146, 95% CI [2461, 3831] t(32.4) = 0.68, p = .50 d = 0.21 
2 Mdn = 2407, IQR [1600, 3395] Mdn = 2400, IQR [1642, 3418] W = 250, p = 1.00 r = 0 
3 Mdn = 2134, IQR [1348, 3054] Mdn = 2159, IQR [1209, 2693] W = 266, p = .73 r = .054 
4 Mdn = 1492, IQR [938, 2139] Mdn = 1766, IQR [590, 1982] W = 285, p = .43 r = .12 
5 M = 1223, 95% CI [868, 1578] M = 1045, 95% CI [809, 1280] t(34.5) = 0.87, p = .39 d = 0.27 
6 Mdn = 768, IQR [401, 1316] Mdn = 650, IQR [408, 959] W = 273, p = .61 r = .078 
rln3ac.158C n = 20,  rln3ac.158T n = 25. *p < 0.05. 
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Figure 4.4 Visual motor response of rln3ac.158T and rln3ac.158C from non-
sibling WT 
(A) Charts illustrating locomotor activity over 6 cycles of dark (black bars) and 
light (white bars), with each cycle lasting 1 h. Error bars show 95% CI. p value 
from the interaction term (Genotype x Time) of two-way repeated measures 
ANOVA against the entire dark period. Total locomotor activity was assessed 
every cycle in the first 10 minute (B) and from minute 14–24 (C) of the dark 
period, as well as the whole light period (D). rln3ac.158T and  rln3ac.158C had similar 
levels of activity in all time periods tested (B-D). (B-D) Crosses represent mean 
and error bars represent 95% CI, individual larval measurements were plotted as 
unfilled circles. For data satisfying normality criteria by the Shapiro-Wilk test, p 
values were reported from Welch’s t-test, effect size as Cohen’s d. Otherwise, p 
values were reported from Mann-Whitney test, r reported as non-parametric 
effect size. 
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Table 4.2 Statistical analysis of locomotor activity in the visual motor response of non-sibling WT 
First 10 minutes 
Cycle 
Total locomotor activity (mm) 
p value Effect size rln3ac.158C rln3ac.158T 
1 Mdn  = 1711, IQR [1351, 2193] Mdn = 1825, IQR [1525, 1953] W = 220, p = .82 r = .037 
2 M = 1817, 95% CI [1514, 2121] M = 1526, 95% CI [1526, 1823] t(40.7) = 1.43, p = .16 d = 0.43 
3 Mdn = 1638, IQR [1361, 1886] Mdn = 1711, IQR [1332, 2017] W = 204, p = .54 r = .097 
4 Mdn = 1367, IQR [1055, 1677] Mdn = 1449, IQR [1070, 1691] W = 231.5, p = .98 r = .006 
5 Mdn = 1023, IQR [877, 1194] Mdn = 1159, IQR [869, 1368] W = 194, p = .39 r = .13 
6 Mdn = 926, IQR [682, 1085] Mdn = 1050, IQR [635, 1271] W = 198, p = .45 r = .12 
Minute 14–24 
Cycle 
Total locomotor activity (mm) 
p value Effect size rln3ac.158C rln3ac.158T 
1 Mdn = 745, IQR [462, 1465] Mdn = 1069, IQR [774, 1576] W = 201, p = .49 r = .11 
2 Mdn = 667, IQR [417, 1638] Mdn = 965, IQR [365, 1525] W = 227, p = .95 r = .011 
3 Mdn = 281, IQR [202, 1044] Mdn = 488, IQR [221, 1365] W = 187, p = .30 r = .16 
4 Mdn = 148, IQR [81.4, 224] Mdn = 281, IQR [107, 483] W = 185, p = .28 r = .17 
5 Mdn = 67.1, IQR [44.4, 96.0] Mdn = 79.3, IQR [38.7, 174] W = 217, p = .76 r = .048 
6 Mdn = 64.3, IQR [27.9, 106] Mdn = 84.7, IQR [50.8, 166] W = 184.5, p = .27 r = .17 
rln3ac.158C n = 14,  rln3ac.158T n = 14. *p < 0.05. 




Table 4.2 Statistical analysis of locomotor activity in the visual motor response of non-sibling WT (continued) 
Whole light period 
 Total locomotor activity (mm)   
Cycle rln3ac.158C rln3ac.158T p value Effect size 
1 M = 4722, 95% CI [3863, 5581] M = 4619, 95% CI [3805, 5433] t(40.4) = 0.18, p = .86 d = 0.055 
2 M = 3962, 95% CI [3261, 4663] M = 3877, 95% CI [3204, 4550] t(40.6) = 0.18, p = .86 d = 0.056 
3 M = 2706, 95% CI [2163, 3248] M = 3222, 95% CI [2574, 3870] t(40.5) = 1.27, p = .21 d = 0.38 
4 Mdn = 1717, IQR [1203, 2213] Mdn = 2341, IQR [1351, 3024] W = 181, p = .24 r = .18 
5 Mdn = 1168, IQR [744, 1784] Mdn = 1528, IQR [853, 1914] W = 207, p = .59 r = .085 
6 Mdn = 589, IQR [429, 989] Mdn = 803, IQR [499, 1663] W = 186, p = .29 r = .16 
rln3ac.158C n = 14,  rln3ac.158T n = 14. *p < 0.05. 
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4.3 Discussion 
Initially, the C-peptide was dismissed as unimportant in Rln3 function due to its 
lack of conserved residues, compared to the A- and B-chains (Wilkinson et al. 
2005). The zebrafish A- and B-chains have 79% and 86% sequence identity to 
human RLN3 respectively (Donizetti et al. 2009), compared to 21% in the 
zebrafish Rln3 C-peptide. In this study, fish possessing the rln3ac.158T allele 
exhibited increased activity in the visual motor response compared with fish 
possessing the rln3ac.158C allele. This effect is only seen in one of the two genetic 
backgrounds tested, indicating that it is likely that gene interactions are occurring 
and contributing to the effect.  
 
In Rln3 null mutant mice, the genetic background of the mice was thought to be 
the reason for contradicting phenotypes in feeding and stress responses, where 
mice with mixed genetic backgrounds displayed decreased body weight (Sutton 
et al. 2009) and slight hypersensitivity to stress (Smith et al. 2009), although 
these differences were not detected in backcrossed Rln3a null mutant mice 
(Smith et al. 2012). Hence, it is likely that genetic background would affect the 
phenotypes detected in the rln3asq4sj-/- mutant line as well. Mutants were 
outcrossed twice before behavioural testing to dilute potential CRISPR off-target 
effects, which could introduce different polymorphisms. Although mutants were 
outcrossed to the same AB WT strain, genetic variability within inbred zebrafish 
strains are estimated to be as high as 7% (Guryev et al. 2006). One genetic 
difference between tested groups in this study is the presence of the c.158C>T 
polymorphism in WT siblings. rln3asq4sj-/- mutants always inherited the c.158C= 
form, implying genetic linkage, which may obscure mutant effects (Gerlai 1996).  
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As the c.158C>T polymorphism causes a non-synonymous change in the amino 
acid threonine to isoleucine, it may represent a loss of function, changing from a 
polar amino acid with a reactive hydroxyl group to one that has a hydrophobic, 
non-reactive side chain (Betts & Russell 2003). Due to the proximity of the 
substituted residue to the cleavage site of the propeptide, it may affect its 
processing, although it does not reside in the furin convertase cleavage site 
(RWRR) which lies between the B- and C-chain (Liu et al. 2003b).  
 
The RLN3 C-peptide was found to have distinct neuronal activity in cultured rat 
hippocampal neurons, and the C-peptide induced sustained calcium activity than 
the RLN peptide (Brailoiu et al. 2009). This role could be unrelated to RLN3 
function, as the peptide has different receptor binding efficiencies to brain 
membranes than RLN3. However, despite a potential behavioural function in 
zebrafish, the highly non-conserved nature of C-peptide indicates that this might 
be a species-specific function. 
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5. GENERAL DISCUSSION AND FUTURE DIRECTIONS 
5.1 General discussion 
To better understand the behavioural role of the neuropeptide RLN3, zebrafish 
rln3a mutants were created, which introduced the genetic study of a different 
organism into the RLN3 field. An optimised protocol using the CRISPR/Cas9 
system was developed, producing zebrafish mutants within a week, and allowed 
the successful generation of nine mutant variants in three rln3-related genes 
(Table 2.6). The mutant with a 7 bp deletion in the rln3a gene (mutant allele 
denoted as rln3asq4sj-/-, Figure 2.1) was chosen for further behavioural analysis. 
 
rln3asq4sj-/- mutants were compared with WT siblings in behaviours known to be 
affected by RLN3 in rodents, such as stress and anxiety, and body weight. In the 
novel tank diving assay, zebrafish displayed mildly reduced anxiety levels, where 
it was only significantly different from WTs in the first minute. If exposed to stress 
prior to the assay, locomotion was significantly decreased in mutants but not in 
WTs, implying sensitivity to stress (Figure 3.2). Mutants displayed significantly 
reduced body weight in week 5 compared to WT, although body weights in the 
two groups remained similar subsequently (Figure 3.4). These findings are 
consistent with mouse null mutation studies, where only mild changes were 
observed (Figure 3.6).  
 
Additionally, the visual motor response was introduced to study the effects of 
Rln3 function. This was to test if rln3a was acting downstream of the dHbL via the 
interpeduncular nucleus which projects to the PAG and NI, which presumably 
would have resulted in delayed recovery of dark-evoked hyperactivity (Agetsuma 
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et al. 2010). However, the visual motor response was similar in both groups of 
fish (Figure 3.3). One problem with using knockout mutations is that 
compensation can occur, allowing the animal to adapt to the loss of the gene. 
This could be a reason why only mild differences in behaviour were observed. 
The paralogue rln3b was upregulated by four-fold in mutants compared to WTs 
(Figure 3.5), indicating that it was possibly compensating by for the loss of rln3a. 
 
A SNP was discovered (rln3ac.158C>T) in the WT siblings of the mutants that were 
used for behavioural testing (Figure 4.1, Figure 4.2). When WT siblings were 
tested in the visual motor response, fish with the rln3ac.158T allele were 
hyperactive in the early dark period (first 10 minutes) compared to fish with the 
rln3ac.158C allele (Figure 4.3).  However, using the non-sibling WT fish, there was 
no difference in behaviour between these two groups (Figure 4.4). This implies 
that the C-peptide may have a function in the behaviour, and behavioural effects 
are susceptible to different genetic backgrounds. 
 
5.2 Future directions 
One conclusion is that the loss-of-function via genetic mutation fails to provide 
evidence for a role of Rln3 in behaviours that have been proposed to involve the 
peptide. Although studying mutants are one way to elucidate biological functions, 
there are multiple problems in the method of testing that may result in the lack of 
a distinct phenotypic abnormality (Barbaric et al. 2007). A main consideration is 
that biological systems are robust, and are often able to adapt despite the 
removal of a single component. The Rln3/RXFP3 system in zebrafish has 
duplicated members due whole genome duplication in teleosts (Good et al. 2012, 
Yegorov et al. 2014), and there were attempts to mutate multiple components 
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simultaneously using efficient CRISPR methods to create double knockouts of 
ligand and receptors.  However, CRISPR/Cas9 introduced multiple alleles with 
varying indels. This mosaicism caused difficulties in mutation detection and 
screening. It became increasingly difficult to maintain multiple mutation lines 
concurrently; therefore a single clean mutation was used for behavioural testing. 
Also, neuropeptide systems are somewhat redundant in nature, and a variety of 
neuropeptides act together to control complex behaviours such as feeding and 
arousal, and compensation is likely to occur.  
 
Two alternative methods are proposed to overcome this issue. Firstly, a heat 
shock-induced overexpression line with the heat shock promoter 70 (hsp70) can 
induce acute gain-of-function, such that compensation will not take place 
(Halloran et al. 2000). This method has been used to overexpress various 
neuropeptides in zebrafish, allowing effective and detailed analysis of how these 
neuropeptides affect sleep (Woods et al. 2014).  
 
In preliminary studies, a transgenic line Tg(hsp70:rln3a-T2A-GFP) was 
generated, and demonstrated to increase rln3a expression after incubating larvae 
at 37°C for 1 h (Figure 5.1). Cells expressing rln3a mRNA were observed in the 
entire zebrafish larvae using ISH, even in the trunk, verifying the construct used 
for overexpression. However, using qRT-PCR to quantify levels of expression 
showed that rln3a transcripts returned to baseline levels 75 min after the 
removing fish from 37°C. This was insufficient time to conduct behavioural 
experiments and more optimisation was required before these larvae can be used 
reliably. 
 




Secondly, driver lines can be created for Rln3a-producing neurons. This could be 
done by knocking in transgenes into the rln3a locus as an extension of CRISPR 
capabilities. Several knock-in methods have been presented to insert large 
transgenes into targeted gene loci (Auer et al. 2014a, Bedell & Ekker 2015, 
Hisano et al. 2015, Kimura et al. 2014, Li et al. 2015, Sakuma et al. 2015), but 
 
Figure 5.1 Heat shock overexpression of rln3a 
(A-D) ISH of rln3a in Tg(hsp70:rln3a-T2A-GFP) larvae at 4 dpf before heat shock. 
(A) Head, dorsal view.  (B) Head, lateral view. (C) Whole larvae, dorsal view. (D) 
Whole larvae, lateral view. (E-H) ISH of rln3a in Tg(hsp70:rln3a-T2A-GFP) larvae 
at 4 dpf after heat shock at 37°C for 1h. (E) Head, dorsal view. (F) Head, lateral 
view. (G) Whole larvae, dorsal view. (H) Whole larvae, lateral view. (I-J) 
Quantitative reverse-transcriptase PCR showing expression levels of rln3a 
without heat shock (no HS), and at time points after the heat shock expressed as 
normalised threshold cycle values (I) or fold change (J). By about 75 minutes, 
rln3a expression returned to baseline levels. Individual fish are plotted as unfilled 
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these methods have proven to be technically difficult. Instead of attempting to 
insert full-length transgenes into the genome, small, single stranded DNAs could 
be inserted more easily (Bedell & Ekker 2015, Bedell et al. 2012). Hence, an attP 
landing site for PhiC31 transposase (Lu et al. 2011, Mosimann et al. 2013) was 
used for insertion into the rln3a locus (Figure 5.2), providing a specific site for 
recombination of a separate construct containing the desired transgene. Although 
50% of the F0 injected fish contained the inserted fragment as detected by PCR, 
the germline transmission rate was too low, and attempts at producing an F1 
generation were unsuccessful. 
 
 
Figure 5.2 Insertion of attP landing site into the rln3a locus using ssDNA 
(A) Schematic diagram of rln3a gene. CRISPR target located in exon 1 shaded in 
grey. Homology arms were taken 50 bp upstream and downstream of the 
CRISPR cut site. (B) Schematic diagram of the ssDNA design used, consisting of 
the attP site flanked by arms homologous to the rln3a cut site. (C) Sequencing 
chromatogram showing insertion of the attP site into injected fish. DNA from 
mosaic injected fish fins was cloned into the vector pGEM-T Easy (Promega) to 
obtain clean sequences. The chromatogram labelled ‘attPin’ represents allele 
with attP site inserted into the rln3a CRISPR target site. The WT chromatogram is 
also shown, while ‘Ref’ represents the annotated reference sequence of the rln3a 
CRISPR site with the inserted attP site. 
5' GAAGACCTCGGCTCTCGTAGTGTGTCTGCTGCTGGCTGGAGTAAAGGCGCCCCCCAACTGAGAGAACTCAAAGGTTACCCCAGTTGGGGGTGGACGCCGGGCCCTCGTATGGAGTCAAATTATGCGGCAGGGAGTTCATC 3'
5’ homology arm (50bp) 3’ homology arm (50bp)attP site (40bp)
Schematic of ssDNA used to insert attP site




Schematic of CRISPR cut in rln3a gene
5' GAAGACCTCGGCTCTCGTAGTGTGTCTGCTGCTGGCTGGAGTAAAGGCGC TGGACGCCGGGCCCTCGTATGGAGTCAAATTATGCGGCAGGGAGTTCATC 3'
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Inserting the transcription activator Gal4 can into the rln3a locus could allow 
specific manipulations in Rln3-expressing neurons when combined with 
transgenes, such as optogenetic tools, or toxins such as tetradotoxin (Asakawa 
et al. 2007) or nitroreductase (Curado et al. 2008), coupled to the upstream 
activator sequence (Halpern et al. 2008, Scheer & Campos-Ortega 1999). This 
would provide more specific tools to improve the understanding of the role of 
Rln3a in the zebrafish brain and how it controls behaviour. 
 
Moreover, it would be interesting to investigate the involvement of the PAG in the 
visual motor response. One study would be to determine if the cells containing 
Rln3a are the ones that activated to dark stimuli. Having a driver line that 
expresses a fluorescent reporter in Rln3a-containing cells will allow easy 
identification of these cells within the PAG. This would greatly improve the 
localisation of these cells, as the only available method currently is ISH, which 
has limited resolution. 
 
Another direction would be to conduct more studies to investigate the behavioural 
effects of the SNP in the C-peptide, which has demonstrated some effect in the 
visual motor response. This can be done by overexpressing the peptide and 
testing for behaviour. Furthermore, other RLN3-associated behaviours can be 
tested. However, it would be important to know which cells respond to the 
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